>
volge

The $8 Billion Gap : State of Play of Indian MedTech

INDIAN MEDTECH · STATE OF PLAY 2026
One of the world’s great buyers of medical devices, and one of its smaller makers. The import bill is the measure of the prize.
~$16B
market, 2025
~70%
devices imported
$50B
2030 policy target
India 2026

State of Play is a read on a sector: its size, its structure, where the money moves and what moves it. Each edition takes one market and sets out what is known, what is claimed, and what the difference between the two is worth to anyone deciding where to commit.

One of the world’s great buyers of medical devices, and one of its smaller makers. The import bill is the measure of the prize. A premium briefing on India’s medical-technology market, the size, the import dependence, the policy push, and the categories where India’s edge is real.

Figures carry their basis and their date. Where published estimates disagree, the range is given and the basis named rather than averaged away, and where a widely quoted number does not survive checking it is corrected here rather than repeated. Every chart plots a figure stated in the text, and nothing is projected beyond what a named source projects.

Contents

01Introduction
  1. 02The import bill is the prize, but the prize is uneven
  2. 05A market that buys what it cannot make
  3. 06Large, growing, and short of its target
  4. 07The import bill, decomposed
  5. 09What India makes, what it buys
  6. 10The demand beneath the market
  7. 11The payer: Ayushman Bharat and the missing middle
02Deep dive
  1. 14The eight categories
  2. 15Where India’s edge is real
  3. 16The high-value wall
  4. 17The regulator: CDSCO and the rules of 2017
  5. 19The new devices bill
  6. 20The economics of the price cap
  7. 21The inverted duty, and the own-goal
03Real-world application
  1. 24The policy push
  2. 25The PLI scheme: what the money built
  3. 26The device parks
  4. 28The exporter: Poly Medicure goes global
  5. 30The implant champions: Meril and SMT
  6. 31The consolidation: KKR and Healthium
  7. 32The multinationals in India
  8. 33The capital and the deals
  9. 35Exports: the edge, sold abroad
  10. 36Clinical AI and software-as-a-medical-device
04The read
  1. 39India versus China
  2. 40The 2030 gap
  3. 41The constraints that gate the climb
  4. 43Market access, and what could go wrong
  5. 44The next two to three years
  6. 46The read, on a page
  7. 47Key takeaways
  8. 48Volge's expertise in MedTech
  9. •Sources
MedTechState of Play01 •

The import bill is the prize, but the prize is uneven

India has spent a decade promising to build a medical-device industry. The size of that promise, and the distance it still has to travel, are written in a single number.

India is among the world’s largest buy­ers of med­ical devices. It is among the smal­lest makers. It im­ports roughly 70% of them, and nearer 85% of the ex­pens­ive sort, the CT scan­ners, stents and dia­lysis ma­chines that fill its hos­pit­als. The mar­ket they sup­ply was worth about $16 bil­lion in 2025. That is usu­ally cast as a fail­ure of in­dus­trial policy. It is bet­ter seen as a meas­ure of the op­por­tun­ity. Every dol­lar spent on an im­por­ted device is one a do­mestic maker might even­tu­ally cap­ture.

The trouble is that the prize is un­evenly spread, and the of­fi­cial am­bi­tion has run well ahead of the maths. New Delhi’s 2023 policy prom­ised to grow the sec­tor to $50 bil­lion by 2030. By 2026 its own min­is­ters were quot­ing $30 bil­lion; in­de­pend­ent ana­lysts model $22–27 bil­lion. Sub­sti­tu­tion is hap­pen­ing, but slowly, and only in places. Three things fol­low.

  • Sub­sti­tu­tion is not one mar­ket but eight. India already makes and ex­ports the low-value end (con­sum­ables, syr­inges, basic IVD); it still im­ports al­most all of the high-value end (ima­ging, im­plants). The cat­egor­ies move at dif­fer­ent speeds.
  • The con­straint is the com­pon­ent, not the will. India im­ports 70–85% of high-value com­pon­ents, runs medtech R&D below 1% of rev­enue, and prices its devices under hard caps. The bar­ri­ers to mak­ing, not the ap­pet­ite for it, gate the pace.
  • The edge is in soft­ware, not steel. Where India struggles to make a CT scan­ner, it can write the AI that reads its im­ages. Clin­ical AI and soft­ware-as-a-med­ical-device are where the coun­try can leapfrog rather than catch up.

So the op­por­tun­ity is real and large, but it is won cat­egory by cat­egory, by the firms that crack the com­pon­ent-and-cap­ab­il­ity prob­lem, not by any­one chas­ing the head­line num­ber.

The fig­ures most often quoted for the policy re­sponse were wrong rather than merely stale, and the cor­rec­tion should travel with this ar­gu­ment. Cu­mu­lat­ive sales of ₹2,315.44 crore, ex­ports of ₹508.12 crore and im­ports avoided of ₹1,807.32 crore have been widely re­peated as the achieve­ment of the med­ical-device pro­duc­tion-linked in­cent­ive. They be­long else­where. The bulk-drugs scheme car­ried them, and they have since been with­drawn. The device scheme's own meas­ure is cu­mu­lat­ive eli­gible sales of ₹13,624.52 crore to Decem­ber 2025, of which ₹6,425.48 crore was ex­por­ted, with 24 green­field pro­jects com­mis­sioned and 57 products in pro­duc­tion (De­part­ment of Phar­ma­ceut­ic­als, 2026). The sub­sti­tu­tion achieved is ac­cord­ingly some six times lar­ger than the with­drawn fig­ures im­plied, and still small against the mar­ket it is meant to dis­place.

The second mis­la­bel runs the other way. The line "in­vest­ment real­ised ₹33,534 crore against a pro­jec­ted ₹17,275 crore" is often cited as evid­ence

MedTechState of Play02 •

of the device scheme over-de­liv­er­ing. It be­longs to the Phar­ma­ceut­ic­als pro­duc­tion-linked in­cent­ive scheme and not to devices. On that scheme's own basis the real­ised fig­ure now stands at ₹46,744 crore as at June 2026 (De­part­ment of Phar­ma­ceut­ic­als, 2026). No com­par­able over-de­liv­ery has been re­cor­ded for devices, where ₹266.64 crore had been re­leased as in­cent­ives to FY2024-25 against the ₹3,420 crore out­lay (Lok Sabha reply, 24 July 2026).

Figures widely quoted for the device incentive belong to other schemes entirely
₹ crore
Pharma, realised 202646,744Pharma, as cited33,534Pharma, projected17,275Device PLI outlay3,420Device incentives paid266.6
Source: Department of Pharmaceuticals, 2026

The prize it­self has also been re-meas­ured, and it is now car­ried as a range. Device im­ports stood at ₹89,000 to 94,700 crore for FY2025-26 de­pend­ing on the trade bas­ket ap­plied, against ex­ports of ₹28,106 crore (Med­ical Buyer, Oc­to­ber 2026). Im­ports meet roughly 60 per cent of do­mestic con­sump­tion on the Gov­ern­ment's own meas­ure, a lower fig­ure than the 70 per cent de­pend­ence usu­ally quoted, the dif­fer­ence being one

of bas­ket rather than of fact. Neither cor­rec­tion dis­turbs the ar­gu­ment. Both sharpen the scale at which it should be read.

Substitution is happening, but slowly, and only in places.
MedTechState of Play03 •

The part in brief

  1. 01Roughly 70 per cent of India's medical devices are bought abroad, and nearer 85 per cent of the costly ones, in a market worth about $16 billion in 2025.
  2. 02The 2023 policy promised $50 billion by 2030; ministers were quoting $30 billion by 2026, and independent models land between $22 and $27 billion.
  3. 03Eight category races make up substitution, not one market: high-value components are 70 to 85 per cent imported and device research runs below 1 per cent of revenue.
  4. 04A correction matters here: the device scheme's own eligible sales reached ₹13,624.52 crore by December 2025, of which ₹6,425.48 crore was exported.
  5. 05The prize is now carried as a range: imports of ₹89,000 to 94,700 crore in FY2025-26 against exports of ₹28,106 crore, with 60 per cent of consumption met abroad.
MedTechState of Play04 •
MedTech

Substitution is happening, but slowly, and only in places.

01

The Problem

A market that buys what it cannot yet make, and the demand that keeps it buying.

A market that buys what it cannot make

India consumes medical technology like a giant and makes it like a minnow. The distance between the two is the whole story.

One asym­metry ex­plains the rest. India runs the fourth-largest med­ical-device mar­ket in Asia, about $16 bil­lion in 2025, yet holds barely 1.5% of the global busi­ness and im­ports some 70% of what it uses. At the top of the range, where the ma­chines are dear and the mar­gins fat, the de­pend­ence is near-total: 80 to 85% im­por­ted, and for im­plants alone, 88 cents on every dol­lar lands from over­seas.

De­pend­ence on that scale car­ries a bill, and the bill is the heart of this story. India’s device trade de­fi­cit hit roughly ₹66,558 crore in FY26, with im­ports run­ning more than three times ex­ports. Tellingly, the gap is widen­ing rather than clos­ing, be­cause de­mand is out­run­ning any­thing the coun­try can yet build. The same num­ber is both the prob­lem and the prize. It is the cost of buy­ing from abroad, and the size of the in­dustry wait­ing to be built at home.

Key takeaways
  • India is a great buyer, small maker of med­ical devices: ~1.5% of the global mar­ket.
India does not lack a medtech market. It lacks a medtech industry, and the difference is the opportunity.
  • ~70% of devices im­por­ted (80–85% of high-value); im­plants ~88%.
  • The trade de­fi­cit is widen­ing: the prize grows even as policy chases it.

The de­pend­ence is not evenly dis­trib­uted across the im­port bill, and the con­cen­tra­tion is the reason sub­sti­tu­tion policy has been able to tar­get it at all. Some 40 product cat­egor­ies ac­count for close to 85 per cent of total med­ical-device im­ports. The Centre is re­por­ted to be re­view­ing eight to ten pri­or­ity cat­egor­ies for ac­cel­er­ated do­mestic pro­duc­tion. The list runs to mag­netic-res­on­ance ima­ging sys­tems and com­pon­ents, pace­makers and con­tinu­ous gluc­ose mon­it­or­ing sys­tems. Ad­vanced ul­tra­sound equip­ment is on it, with com­puted-tomo­graphy and X-ray com­pon­ents, in­tens­ive-care beds, and high-end dia­gnostic ana­lys­ers with their as­so­ci­ated re­agents (India Brief­ing and Med­ical Buyer, 2026).

The sources of sup­ply are sim­il­arly con­cen­trated. The top five ori­gin coun­tries ac­count for around 68 per cent of im­port value. They are China, the United States, Ger­many, Singa­pore and the Neth­er­lands. The United States is the single largest source, with China close to 20 per cent, much

MedTechState of Play05 •

of it in mon­it­ors, ima­ging com­pon­ents, dis­pos­ables and low-cost dia­gnostics (trade data, FY2024). The same mul­tina­tion­als that dom­in­ate the premium seg­ments are them­selves the im­port chan­nel, so the im­port bill and the com­pet­it­ive land­scape are two read­ings of one struc­ture.

The head­line share needs one qual­i­fic­a­tion. The Gov­ern­ment's own po­s­i­tion, stated in Oc­to­ber 2026, is that im­ports meet about 60 per cent of do­mestic con­sump­tion (Med­ical Buyer, Oc­to­ber 2026). That sits against the roughly 70 per cent de­pend­ence fig­ure drawn from a Novem­ber 2024 source, and against the 80 to 85 per cent cited by in­dustry bod­ies for the high-value seg­ments. The three fig­ures are not in con­flict. They meas­ure dif­fer­ent bas­kets at dif­fer­ent dates. The asym­metry they de­scribe is un­changed, and so is its con­sequence.

Import dependence deepens as the value of the device rises
per cent imported
025507510088Implants85High-value devices70All devices, industry60All devices, govt
Source: Medical Buyer, October 2026

Large, growing, and short of its target

How big the market is, everyone roughly agrees. Where it is going, not even the government can decide.

Es­tim­ates of India’s device-mar­ket size dis­agree by a quarter. In­de­pend­ent ana­lysts put 2025 at $15–19 bil­lion; the gov­ern­ment’s own pro­mo­tional fig­ure sits near $14 bil­lion, anchored to an $11 bil­lion baseline from 2022. The spread is mostly defin­i­tional, what counts as a “device,” and which policy tar­gets get quoted as fore­casts. On dir­ec­tion, there is no ar­gu­ment: the mar­ket is grow­ing, and faster than most of the eco­nomy around it.

It is the road to 2030 where the dis­agree­ment starts to mat­ter. The 2023 Na­tional Med­ical Devices Policy set a $50 bil­lion tar­get and a 16% growth rate to reach it. By March 2026, min­is­ters were quot­ing $30 bil­lion. Ana­lysts model $22–27 bil­lion at a 5.5–8% pace. Read to­gether, the num­bers tell a quiet story of re­treat: the of­fi­cial tar­get has already fallen by a third, and even the re­duced ver­sion sits com­fort­ably above what the mar­ket is ac­tu­ally doing.

The mar­ket basis has been re-stated since this read was pre­pared, mod­estly, and the re-state­ment is worth re­cord­ing. A FY2025-26 row is now

MedTechState of Play06 •

car­ried at about US$15 to 16 bil­lion, against about US$14 bil­lion for FY2024-25. The band of cred­ible es­tim­ates is held at US$12 to 18 bil­lion. The com­pet­ing es­tim­ates are worth nam­ing rather than av­er­aging. EY and CII put FY2025-26 at US$12 to 15 bil­lion, in­dustry re­port­ing at US$15 to 16 bil­lion, and one re­search house at US$18.3 bil­lion (re-based Septem­ber 2026). The spread re­mains defin­i­tional. Quot­ing a single point es­tim­ate re­mains un­sound.

Indian medical-device market, reconciled basis
US$ bn
012.52537.55011202214FY2024-2516FY2025-26502030 target
Source: NMDP 2023, EY and CII, 2026

On the growth rate, the re­con­ciled basis is an or­ganic pace of the order of 10 to 15 per cent a year. That is faster than the 5.5 to 8 per cent mod­elled by some in­de­pend­ent ana­lysts, and well short of the near 20 per cent the 2030 tar­get im­plies. In­dustry pro­jec­tions sit between the two, and the Con­fed­er­a­tion of In­dian In­dustry has re­it­er­ated a fig­ure of roughly US$44 to

50 bil­lion by 2030. A sep­ar­ate mar­ket es­tim­ate places the sec­tor at US$18.30 bil­lion in 2026 rising to US$26.66 bil­lion by 2031, a com­pound rate near 7.82 per cent (Med­ical Buyer, 2026).

What this calls for is dis­cip­line rather than fore­cast­ing. The hon­est state­ment of the mar­ket is a range, with its basis named and its date at­tached. The hon­est state­ment of 2030 is a set of com­pet­ing fig­ures. Their spread, from the high twen­ties to fifty bil­lion dol­lars, is it­self the find­ing.

The import bill, decomposed

Not all of India’s dependence is equal. It clusters, precisely, where the money is.

Im­port de­pend­ence has a shape, and the shape is the strategy. India makes its own cheap, high-volume kit and buys al­most everything soph­ist­ic­ated. The par­lia­ment­ary re­cord lays it out: 88% of im­plants im­por­ted, 63% of sur­gical in­stru­ments, 52% of elec­tronic equip­ment, the CT, MRI, ul­tra­sound and X-ray ma­chines, with elec­tromed­ical devices alone ac­count­ing for some 60% of the en­tire im­port bill.

The exact fig­ure de­pends on who is count­ing: the gov­ern­ment’s latest line is ~70% im­por­ted over­all, and in­dustry bod­ies and EY say 80–85%. The pat­tern holds, and the dir­ec­tion is wrong. Across FY21–FY25 India spent

MedTechState of Play07 •

more than $25 bil­lion buy­ing devices abroad; in FY26 alone, im­ports reached roughly ₹94,664 crore against ₹28,106 crore of ex­ports. De­pend­ence runs deep­est ex­actly where mar­gins, tech­no­logy and stra­tegic weight are greatest, which is why the loc­al­isa­tion that mat­ters most is the loc­al­isa­tion that is hard­est.

Sources: Par­lia­ment­ary Stand­ing Com­mit­tee 2022/2024; Rajya Sabha reply 2025; DGCIS FY26. Coun­try-level im­port shares are not of­fi­cially pub­lished.

The im­port fig­ure should now be car­ried as a range rather than a point, be­cause two trade bas­kets are in cir­cu­la­tion and they do not agree. Im­ports of about ₹89,000 crore are re­cor­ded for FY2025-26 on the nar­rower device bas­ket, a rise of roughly 17 per cent on about ₹63,000 crore in FY2024. The wider bas­ket re­cords ₹94,664 crore. The de­fens­ible state­ment is there­fore ₹89,000 to 94,700 crore, with the bas­ket named (DrugsControl Media Ser­vices, 2026; Med­ical Buyer, Oc­to­ber 2026).

The rise is not a single year's event. Im­ports had already risen by ap­prox­im­ately 21 per cent to about ₹61,263 crore in the twelve months from Novem­ber 2022 to Oc­to­ber 2023. Some 2024 trade com­pil­a­tions, drawn across broader cus­toms codes, re­port gross med­ical-equip­ment im­ports as high as US$18 bil­lion. Of that, elec­tromed­ical equip­ment ac­counts for US$5.4 bil­lion and ima­ging US$4.2 bil­lion, with con­sum­ables US$3.9 bil­lion, im­plants US$2.8 bil­lion and in­ter­ven­tional devices US$1.6 bil­lion (Busi­ness Stand­ard, 2024). That wider scope is not the basis used in this read, and the two should not be set side by side.

Device trade, FY2025-26 against the FY2024 base
₹ crore
025,00050,00075,000100,00063,000Imports, FY202489,000Imports, FY2025-26(narrow basket)94,664Imports, FY2025-26(wider basket)28,106Exports, FY2025-26
Source: Medical Buyer and DrugsControl Media Services, 2026

One fur­ther meas­ure cuts against the head­line. On the Gov­ern­ment's own state­ment of Oc­to­ber 2026, im­ports meet roughly 60 per cent of do­mestic con­sump­tion. The num­ber is lower than the de­pend­ence shares quoted above and is not in­con­sist­ent with them: con­sump­tion, value of devices in use, and the high-value sub-bas­ket are three dif­fer­ent de­nom­in­at­ors. The dir­ec­tion of travel is the point on which all three agree, and it re­mains ad­verse.

The pat­tern ex­plains the op­por­tun­ity and its cruelty at once. The cat­egor­ies India already owns are the ones with the thin­nest mar­gins; the cat­egor­ies worth real money are the ones it can­not yet build. Sub­sti­tu­tion, then, is

MedTechState of Play08 •

not a single climb but a series of sep­ar­ate as­cents, each gated by its own mix of cap­ital, com­pon­ents and clin­ical-grade qual­ity.

What India makes, what it buys

Draw a line through India’s device industry by technical difficulty, and it sorts the market almost perfectly.

India’s device in­dustry is not feeble every­where: it is for­mid­able at one end and ab­sent at the other, and tech­nical com­plex­ity sep­ar­ates them:

  • India makes, and ex­ports. Con­sum­ables and dis­pos­ables: syr­inges, needles, cath­et­ers, gloves, tubing. Firms like Hindus­tan Syr­inges and Poly Med­i­cure run genu­ine global busi­nesses, and India holds a trade sur­plus in these low-tech items.
  • India im­ports: al­most en­tirely. Dia­gnostic ima­ging (GE, Philips and Siemens dom­in­ate), or­tho­paedic and car­diac im­plants (only a frac­tion of Class III im­plants are made loc­ally), pace­makers, hear­ing aids and dental im­plants.
  • India is mixed. In-vitro dia­gnostics and sur­gical in­stru­ments, basic items do­mestic, high-end im­por­ted, the con­tested middle where sub­sti­tu­tion is act­ively being fought.

Be­neath the fin­ished-device split lies a second and harder de­pend­ence, and it is the one that de­term­ines how much of the ap­par­ent loc­al­isa­tion is

real. Roughly 30 to 40 per cent of up­stream in­puts re­main im­port-sourced, chiefly spe­cialty ma­ter­i­als and elec­tron­ics, along with sensors. Much of it comes from China (Med­ical Buyer, 2026). Im­port­ing com­pon­ents in­flates a star­tup's costs by an es­tim­ated 20 to 40 per cent. The con­flict in West Asia is re­por­ted to have raised input costs on some lines by 10 to 50 per cent. A thin com­pon­ent base trans­mits ex­ternal shocks straight into device prices.

The policy re­sponse has begun to move up­stream ac­cord­ingly. The ₹500 crore Scheme for Strength­en­ing the Med­ical Device In­dustry, launched in Novem­ber 2024, funds key-com­pon­ent man­u­fac­ture spe­cific­ally to sub­sti­tute im­ports, and the De­part­ment of Phar­ma­ceut­ic­als has set out a plan to loc­al­ise 113 af­ford­able devices over five years. A one-time re­im­burse­ment cap­ital sub­sidy of up to ₹10 crore is on offer under the as­so­ci­ated Mar­ginal In­vest­ment Scheme for com­pon­ents, raw ma­ter­i­als and fin­ished devices presently im­por­ted in quant­ity (De­part­ment of Phar­ma­ceut­ic­als, 2026).

Two fur­ther gates now sit across the same map. Con­form­ity to the Bur­eau of In­dian Stand­ards Scheme X be­came a con­di­tion of law­ful man­u­fac­ture and im­port for no­ti­fied devices from 1 Septem­ber 2026. The De­part­ment's re­view of the 354-device Global Tender En­quiry ex­emp­tion list, on which pub­lic-pro­cure­ment ac­cess for im­por­ted equip­ment turns, re­mained pending de­cision as at Oc­to­ber 2026. The cat­egor­ies India buys are

MedTechState of Play09 •

there­fore being con­tested by stand­ards and pro­cure­ment rules as much as by factor­ies.

The demand beneath the market

Whatever happens on the supply side, the demand is not going anywhere. It is vast, and it is built in.

The mar­ket grows be­cause the need is enorm­ous and rising. India car­ries one of the heav­iest chronic-dis­ease loads on earth. Roughly 101 mil­lion people have dia­betes and 136 mil­lion more are on its edge, with an es­tim­ated 315 mil­lion liv­ing with hy­per­ten­sion. There were about 1.46 mil­lion new can­cer cases in 2022, head­ing to­ward 1.57 mil­lion by 2025. Car­di­ovas­cu­lar dis­ease kills more than one In­dian in four. Every one of those num­bers is a device mar­ket, for mon­it­ors, stents, im­plants, scan­ners and tests.

The ca­pa­city to treat all of it lags far be­hind. India has about 1.3 to 1.4 hos­pital beds per 1,000 people against a WHO bench­mark of 3.5, and pub­lic fa­cil­it­ies man­age just 0.79. The short­fall is put at some 2.4 mil­lion beds. Demo­graphy only tight­ens the screw. The over-60 pop­u­la­tion is set to double to 346 mil­lion by 2050, roughly a fifth of the coun­try. A vast, age­ing, under-equipped pop­u­la­tion will need more devices every year for

Three chronic-disease pools, each of them a device market in itself
million people
0100200300400315Hypertension136Pre-diabetes101Diabetes
Source: reconciled basis, 2026

dec­ades. The open ques­tion is not whether the de­mand ex­ists. It is who fills it.

Key takeaways
  • India car­ries a vast chronic-dis­ease bur­den: ~101m dia­betic, ~315m hy­per­tens­ive.
  • Ca­pa­city lags: ~1.3 beds/1,000 (govt 0.79): a ~2.4m-bed short­fall.
  • The 60+ pop­u­la­tion doubles to 346m by 2050: de­mand rises for dec­ades.

The pay­ment struc­ture de­cides which devices win, and in India it is weighted un­usu­ally to­wards the pa­tient. Out-of-pocket spend­ing ac­counts for in ex­cess of 60 per cent of total health­care ex­pendit­ure in India. That fea­ture gov­erns the pri­cing and the dis­tri­bu­tion of any­thing in­ten­ded

MedTechState of Play10 •
Hospital-bed provision in India runs well below the international benchmark
beds per 1,000 people
012343.5WHO benchmark1.3India, all beds0.8Public facilities
Source: WHO

for the In­dian pa­tient, and it dom­in­ates dia­gnostics and pa­tient-fa­cing devices in par­tic­u­lar (re­con­ciled basis, 2026). Private in­sur­ance re­im­burses typ­ic­ally 50 to 80 per cent of cost at more fa­vour­able rates but on lower volume. Cor­por­ate group cover is a smal­ler and con­cen­trated pool.

The fast­est-grow­ing ex­pres­sion of that de­mand is care de­livered out­side the hos­pital. The In­dian home-health­care mar­ket was es­tim­ated at ap­prox­im­ately US$11.9 bil­lion in 2025, grow­ing at about 18 per cent a year to­wards US$27 bil­lion by 2030. Re­mote pa­tient mon­it­or­ing within it is grow­ing faster still, at around 25 per cent (Mordor In­tel­li­gence, 2025). Hos­pital-at-home and vir­tual-in­tens­ive-care mod­els are gain­ing ground. That moves de­mand to­wards mon­it­or­ing, point-of-care dia­gnostics and soft­ware rather than to­wards cap­ital equip­ment.

Parts of the de­mand re­main con­spicu­ously un­der­served. The In­dian femtech mar­ket was es­tim­ated at ap­prox­im­ately US$310 mil­lion in 2025. It is pro­jec­ted to grow at roughly 17 to 18 per cent a year to­wards US$3.87 bil­lion by 2030, with some 346 act­ive com­pan­ies hav­ing col­lect­ively raised about US$271 mil­lion as at early 2026 (Frost & Sul­li­van and Tracxn, 2026). Pae­di­at­ric and neonatal devices re­main un­der­developed re­l­at­ive to need. The de­mand is not in ques­tion. Its dis­tri­bu­tion is.

The payer: Ayushman Bharat and the missing middle

Demand only becomes a market when somebody pays for it. In India, that somebody is now, overwhelmingly, the government.

A med­ical need turns into device de­mand only once it is fun­ded. India’s fund­ing has tilted to­ward pub­lic in­sur­ance. Ay­ush­man Bharat, the PM-JAY scheme, now reaches some 12 crore fam­il­ies and over 50 crore people, with a ₹5 lakh an­nual cover per fam­ily and nearly 44 crore cards is­sued. More than 10 crore hos­pital ad­mis­sions have been paid for across roughly 36,000 em­pan­elled hos­pit­als. A 2024 ex­pan­sion swept in every cit­izen over 70 re­gard­less of in­come, adding about 6 crore seni­ors.

MedTechState of Play11 •

The state has be­come the single largest force shap­ing what devices get bought.

What Ayushman Bharat now reaches, counted in crore
crore
People covered50Cards issued44Families covered12Admissions paid10Seniors added, 20246
Source: PIB and PMO, September 2024

But a hole sits in the middle of the sys­tem. Only about 20% of In­di­ans hold health in­sur­ance, and roughly 30%, the “miss­ing middle,” above the poverty line yet without em­ployer or state cover, are ex­posed, with out-of-pocket spend­ing still near 39% of all health spend­ing. For device makers the arith­metic cuts both ways: pub­lic in­sur­ance drives volume and re­wards cheap, loc­ally-rel­ev­ant products, but it also brings the pro­cure­ment dis­cip­line and the price caps that grind down mar­gins. Who pays, and how, de­cides which devices win.

The senior-cit­izen ex­pan­sion is bet­ter spe­cified than it is usu­ally re­por­ted, and its mech­an­ics mat­ter more than its head­line. It was ap­proved by the Union Cab­inet on 11 Septem­ber 2024 with an out­lay of ₹3,437 crore. Cover

ex­tends to all cit­izens aged 70 and above ir­re­spect­ive of in­come, across some 4.5 crore fam­il­ies, and is de­livered through a ded­ic­ated Ay­ush­man Vay Vandana card. Seni­ors in fam­il­ies already covered re­ceive a top-up that is not shared with younger mem­bers (PIB and PMO, Septem­ber 2024). The clin­ical pro­file of that co­hort is device-in­tens­ive, con­cen­trated in car­di­ology, on­co­logy and or­tho­paed­ics.

The mech­an­ism re­wards cost lead­er­ship rather than in­nov­a­tion. Re­im­burse­ment is fixed per pro­ced­ure and in­clus­ive of the device or im­plant, so the pull is felt as higher pub­lic-sys­tem volume rather than as higher unit price. Pro­cure­ment is routed through the Cent­ral Med­ical Ser­vices So­ci­ety, HLL Infra Tech Ser­vices, the Gov­ern­ment e-Mar­ket­place and the state med­ical ser­vices cor­por­a­tions, under pooled tenders and rate con­tracts mod­elled on the Tamil Nadu cor­por­a­tion. Pro­cure­ment pref­er­ence is given to Class-I local sup­pli­ers under the Pub­lic Pro­cure­ment (Pref­er­ence to Make in India) Order.

The com­mer­cial con­sequence is a chan­nel of enorm­ous volume and un­at­tract­ive terms. Pro­cure­ment timelines com­monly run 12 to 24 months, pay­ment cycles ex­ceed 90 days, and gov­ern­ment schemes re­im­burse high-volume as­says at ₹50 to 200 per test. A man­u­fac­turer built for a low cost of goods, with a Gov­ern­ment e-Mar­ket­place list­ing and the pa­tience for the pub­lic tender cycle, can reach scale through this chan­nel. One that re­quires premium pri­cing should treat the pub­lic sys­tem as a ref­er­ence cus­tomer rather than as the core mar­ket.

MedTechState of Play12 •

The part in brief

  1. 01Dependence deepens with value: 80 to 85 per cent of high-value devices are imported, 88 per cent of implants, and five origin countries supply about 68 per cent.
  2. 02Market size is a range, not a point: credible FY2025-26 estimates run from US$12 billion to US$18.3 billion, and the 2030 target has already slipped.
  3. 03Imports concentrate: electromedical devices alone are some 60 per cent of the bill, and 40 product categories cover close to 85 per cent of all device imports.
  4. 04Demand is structural: about 101 million Indians have diabetes and 315 million live with hypertension, while beds run at 1.3 per thousand against a 3.5 benchmark.
  5. 05The payer now sets the terms: PM-JAY reaches over 50 crore people at ₹5 lakh a family, yet only about 20 per cent of Indians hold health insurance.
MedTechState of Play13 •
The Problem

India does not lack a medtech market. It lacks a medtech industry, and the difference is the opportunity.

02

The Mechanics

The categories, the regulation, and the economics that decide who can make what.

The eight categories

Break the market into its pieces and a clear story falls out, of where India is strong, and where it simply isn’t.

Slice the device mar­ket by seg­ment and the rank­ings hold even as the exact shares wobble between sources. Dia­gnostic ima­ging is the biggest slice, around 30%, and al­most en­tirely im­por­ted. Con­sum­ables and dis­pos­ables come next, at about 16% of the product mix and more of the trade value. They are India’s home turf. In-vitro dia­gnostics sit near 10%. Or­tho­paed­ics, pros­thet­ics, pa­tient aids and dental trail below.

The shares mat­ter be­cause they show where sub­sti­tu­tion can bite, and where it can’t:

One caveat is in order. Most of these per-seg­ment fig­ures are 2020-vin­tage, and no fresh itemised break­down has been pub­lished. Treat the shares as dir­ec­tional rather than pre­cise. The shape is solid, ima­ging-heavy and im­port-de­pend­ent up top, with con­sum­ables strong at the base [In­sert veri­fied cur­rent seg­ment-share table here when pub­lished].

A second and more re­cent cut dis­agrees with the seg­ment shares quoted here, and the dis­agree­ment is in­struct­ive. On the re­con­ciled eight-cat­egory basis used in Volge's in­ternal work, in-vitro dia­gnostics is the largest seg­ment at 25 to 30 per cent. Sur­gical and or­tho­paedic devices fol­low at 20 to 25 per cent, with ima­ging and ra­di­ology at 15 to 20 per cent. Car­diac

and vas­cu­lar take 10 to 12 per cent, pa­tient mon­it­or­ing and wear­ables 10 to 15 per cent, and the oph­thal­mic, dental and other spe­cial­ised group 5 to 10 per cent (re­con­ciled basis, 2026).

On the reconciled basis, diagnostics rather than imaging is the largest segment
per cent of market, upper end of range
In-vitro diagnostics30Surgical and ortho25Imaging, radiology20Monitoring, wearables15Cardiac and vascular12Ophthalmic and other10
Source: reconciled basis, 2026

Two cat­egor­ies es­cape that basis en­tirely. Con­sum­ables and dis­pos­ables are large by unit volume and are fre­quently coun­ted within other seg­ments, and soft­ware as a med­ical device is an emer­ging cross-cut rather than a line item. The ranges do not sum to one hun­dred per cent, and they are presen­ted as ranges be­cause the un­der­ly­ing es­tim­ate pred­ates the eight-cat­egory split. This is a weaker evid­en­tial po­s­i­tion than a single table im­plies. No fresh itemised break­down has been pub­lished.

What sur­vives the dis­agree­ment is the or­der­ing by cap­ital in­tens­ity, which is the vari­able that ac­tu­ally gov­erns India's po­s­i­tion. Ima­ging and car­diac and vas­cu­lar rank highest, with sur­gical and or­tho­paedic high. In-vitro

MedTechState of Play14 •

dia­gnostics and point-of-care sit in the middle, and mon­it­or­ing, con­sum­ables and soft­ware low. India's po­s­i­tion is close to the in­verse. The share table is there­fore best used to loc­ate the money, and the cap­ital-in­tens­ity column to pre­dict who will make it.

Where India’s edge is real

Set aside the ambition and the subsidies. What India can actually make and sell to the world is narrow, but it is real money.

India’s strength is not an as­pir­a­tion in a policy doc­u­ment. It is vis­ible in what the coun­try already ships. Con­sum­ables make up roughly 47% of med­ical-device ex­ports. In a hand­ful of cat­egor­ies In­dian firms com­pete with any­one on cost and scale. Syr­inges and needles are one (Hindus­tan Syr­inges is among the world’s largest makers), can­nu­lae and cath­et­ers an­other (Poly Med­i­cure sells into more than a hun­dred coun­tries), with basic in-vitro dia­gnostics a third (Transasia, Agappe). Oph­thal­mo­logy, in­traocu­lar lenses and their con­sum­ables, is an­other genu­ine win.

What these win­ners share is telling. They are high-volume and cost-sens­it­ive, where India’s man­u­fac­tur­ing eco­nom­ics and en­gin­eer­ing tal­ent con­vert straight into ad­vant­age; they sit below the reg­u­lat­ory and cap­ital bar of a Class III im­plant; and they re­ward scale, which a bil­lion-strong home mar­ket sup­plies. The edge is real, and bounded. It lives at the value end

India has already conquered, not the fron­tier it still im­ports. Whether those same firms can climb higher is the ques­tion the next pages take apart.

Key takeaways
  • India’s real edge: con­sum­ables, basic IVD, oph­thal­mo­logy: high-volume, cost-led.
  • Con­sum­ables are ~47% of device ex­ports: a won mar­ket.
  • The edge is bounded at the value end; the high-value climb is the open ques­tion.

The breadth of that edge is bet­ter meas­ured in mar­ket reach than in share. In­dian ex­port­ers now serve ap­prox­im­ately 187 coun­tries. The lead­ing firms' in­di­vidual foot­prints are sub­stan­tial. Trivit­ron Health­care re­ports ex­ports across roughly 180 coun­tries, Opto Cir­cuits products in use in more than 150, and Poly Med­i­cure in over 110. Transasia Bio-Med­ic­als is in more than 100, Health­ium Medtech in over 90, and Sahajanand Med­ical Tech­no­lo­gies in more than 40 (com­pany dis­clos­ures and Med­ical Buyer, 2026). The United States is the lead­ing des­tin­a­tion.

The eco­nom­ics be­neath the edge ex­plain why it holds. In-vitro dia­gnostics runs on razor-and-blade terms, an ana­lyser placed at ₹5 to 15 lakh pulling through ₹2 to 5 lakh of re­agent a year. Gross mar­gins run 40 to 60 per cent, with cap­ital to prof­it­ab­il­ity of ₹50 to 100 crore. Point-of-care test­ing is the fast­est-grow­ing sub-seg­ment within it. The oph­thal­mic cluster, led by Auro­lab, Ap­pasamy, Forus Health and Re­mi­dio, com­petes on frugal en­gin­eer­ing rather than on scale alone.

MedTechState of Play15 •
Export reach of India's leading device makers
countries served
Trivitron Healthcare180Opto Circuits150Poly Medicure110Transasia Bio-Medicals100Healthium Medtech90Sahajanand (SMT)40
Source: Company disclosures, 2026

The for­ward view on ex­ports is more op­tim­istic than the do­mestic sub­sti­tu­tion view, and it rests on bet­ter evid­ence. Bain & Com­pany char­ac­ter­ises India as an ac­cess-led in­nov­ator and ex­port hub. It re­cords device ex­ports of about US$4 bil­lion in FY2024-25 to more than 125 coun­tries, and pro­jects growth above 20 per cent com­pound to 2030, po­ten­tially doub­ling ex­ports to nearly US$8 bil­lion (Med­ical Buyer, July 2026). That re­mains well short of the in­dustry's own US$20 bil­lion am­bi­tion for the same date.

The com­pon­ent fig­ure re­quires a note of care, be­cause two meas­ures are in cir­cu­la­tion and they de­scribe dif­fer­ent things. The 70 to 85 per cent cited above is the im­por­ted share of high-value com­pon­ents in high-value devices. On a wider meas­ure of all up­stream in­puts, spe­cialty ma­ter­i­als and elec­tron­ics to­gether with sensors, the im­port share is roughly 30 to 40 per cent, much of it from China (Med­ical Buyer, 2026). Both fig­ures are

de­fens­ible on their own basis. Neither sup­ports the claim that as­sembly in India amounts to in­di­gen­isa­tion.

The high-value wall

Almost every CT scanner and cardiac implant in India is foreign-made. The reasons are structural, and they stack.

At the top of the value curve stands a wall India has not climbed. Dia­gnostic ima­ging, CT, MRI, ul­tra­sound, lin­ear ac­cel­er­at­ors, and high-end im­plants be­long to a hand­ful of global firms (GE HealthCare, Philips, Siemens Health­in­eers, Medtronic, Bo­ston Sci­entific), and India buys the over­whelm­ing ma­jor­ity. The reas­ons are not in­cid­ental; they com­pound:

  • Com­pon­ent de­pend­ence. Even where a device is “as­sembled in India,” 70–85% of high-value com­pon­ents are im­por­ted, de­tect­ors, mag­nets, spe­cial­ised chips, so loc­al­isa­tion is shal­low.
  • R&D in­tens­ity. In­dian medtech spends below 1% of rev­enue on R&D against 8–10% for US and Ger­man firms; global play­ers hold roughly 13 times the pat­ents per dol­lar of rev­enue.
  • Clin­ical-grade qual­ity and trust. High-value devices de­mand long val­id­a­tion, reg­u­lat­ory clear­ance and clini­cian con­fid­ence: a moat of ac­cu­mu­lated cred­ib­il­ity that sub­sidies can­not short­cut.
MedTechState of Play16 •

The PLI scheme is start­ing to chip at the wall. CT, MRI and ul­tra­sound are now built in India in some volume. But as­sembly is not in­di­gen­isa­tion, and the deep­est value still flows off­shore. This wall is why the $50 bil­lion tar­get is so pun­ish­ing. The cheap cat­egor­ies are already won, and the ex­pens­ive ones re­fuse to give.

The cap­ital arith­metic is the second reason the wall holds. Set­ting up ima­ging man­u­fac­ture re­quires cap­ital ex­pendit­ure of the order of ₹20 to 100 crore and more, with op­er­at­ing costs of ₹5 to 15 crore a year and break­even at five to ten years. Sur­gical im­plants re­quire ₹5 to 50 crore of setup and four to seven years. Total cap­ital to prof­it­ab­il­ity runs ₹300 to 600 crore and above for ima­ging sys­tems and ₹150 to 400 crore for im­plants, against ₹30 to 60 crore for a soft­ware dia­gnostic (re­con­ciled basis, 2026). Few do­mestic bal­ance sheets reach that scale.

Where the wall has been breached, the gain is real. Devices pro­duced under the pro­duc­tion-linked in­cent­ive are re­por­ted to be ap­prox­im­ately 10 to 30 per cent cheaper than the im­por­ted equi­val­ents. The scheme's out­put now in­cludes lin­ear ac­cel­er­at­ors, mag­netic-res­on­ance and com­puted-tomo­graphy sys­tems, mam­mo­graphy units and C-arms. Ul­tra­sound equip­ment is on the list, as are heart valves, stents and dia­lysis products (Med­ical Dia­logues and Lok Sabha reply, July 2026). The price ad­vant­age, not the flag of ori­gin, is what will even­tu­ally move pro­cure­ment.

The capital needed to reach profitability separates imaging from software
₹ crore, upper end of range
0150300450600600Imaging systems400Implants60Software diagnostic
Source: reconciled basis, 2026

The regulator: CDSCO and the rules of 2017

For most of its history, India barely regulated medical devices at all. Then, almost overnight, it did, and the system is still absorbing the shock.

India’s device reg­u­lator, the Cent­ral Drugs Stand­ard Con­trol Or­gan­isa­tion (CDSCO), runs a strik­ingly young frame­work. The Med­ical Devices Rules of 2017 took ef­fect in 2018 and im­por­ted four glob­ally-aligned risk classes, A (low, a ther­mo­meter), B (low-mod­er­ate), C (mod­er­ate-high, a

MedTechState of Play17 •

vent­il­ator) and D (high, a heart valve or im­plant­able de­fib­ril­lator). The centre li­censes the ris­kier Class C and D; the states handle A and B.

ClassRiskExample deviceAuthority · mandatory from
ALowThermometersState · Oct 2022
BLow–moderateHypodermic needlesState · Oct 2022
CModerate–highVentilatorsCentral · Oct 2023
DHighHeart valves, implantsCentral · Oct 2023

The hinge came in 2020. A gaz­ette no­ti­fic­a­tion pulled every device under reg­u­la­tion as a drug, end­ing an era in which much of the mar­ket was ef­fect­ively un­po­liced. Li­cens­ing was phased in, Class A and B from Oc­to­ber 2022, C and D from Oc­to­ber 2023, and the ef­fect cut both ways. The mar­ket form­al­ised (there are now over 4,000 li­censed man­u­fac­tur­ers), but the same move ex­posed how thin the plumb­ing is, from a short­age of test­ing labs to a back­log of in­spec­tions. For any maker, for­eign or In­dian, CDSCO clear­ance is no longer op­tional. The re­gime is still matur­ing, but it is now a real gate.

The timelines are the part of this re­gime that de­term­ines whether a ven­ture sur­vives it, and they are routinely un­der­es­tim­ated. Cent­ral Li­cens­ing Au­thor­ity re­view runs typ­ic­ally 90 to 120 days for a Class C device and 120 to 180 days for a Class D device. Full re­gis­tra­tion takes nine to eight­een months where no clin­ical trial is re­quired, and sig­ni­fic­antly longer where

one is. A clin­ical in­vest­ig­a­tion com­monly costs ₹1 to 5 crore and takes twelve to twenty-four months. It is man­dat­ory for in­vest­ig­a­tional Class B, C and D devices without a pre­dic­ate man­u­fac­tured in India and for new in-vitro dia­gnostics (CDSCO and CliniExperts, 2025).

Ca­pa­city and pro­cess are now mov­ing to meet the back­log. A Risk Clas­si­fic­a­tion Mod­ule was brought on­line on 27 Novem­ber 2025, al­low­ing ap­plic­ants to re­quest a clas­si­fic­a­tion for devices not yet on the pub­lished lists. The sanc­tion of 1,500 ad­di­tional posts within the or­gan­isa­tion has been con­firmed, the stated in­tent being spe­cial­ised sci­entific ca­pa­city and shorter eval­u­ation times. The SUGAM portal be­came man­dat­ory for post-ap­proval changes from 1 July 2026. Draft no­ti­fic­a­tion G.S.R. 515(E) of 23 June 2026, pro­pos­ing shortened li­cence timelines for Class B, C and D devices, closed for com­ment on 22 July 2026 (CDSCO and MoHFW, 2026).

Soft­ware has been brought in­side the same frame. The final Guid­ance Doc­u­ment on Med­ical Device Soft­ware was is­sued in Au­gust 2026, su­per­sed­ing the draft of 21 Oc­to­ber 2025. It cov­ers soft­ware as a med­ical device, soft­ware in a device and in-vitro dia­gnostic soft­ware, with an Al­gorithm Change Pro­tocol per­mit­ting pre-spe­cified model up­dates without fresh ap­proval. Final guid­ance of July 2026 ad­di­tion­ally re­quires ar­ti­fi­cial-in­tel­li­gence-en­abled soft­ware to dis­close train­ing-data com­pos­i­tion and bias across India-rel­ev­ant sub-pop­u­la­tions.

MedTechState of Play18 •

The new devices bill

After eight decades, India is rewriting the law over its devices, and, for the first time, refusing to treat them as drugs.

The biggest reg­u­lat­ory shift is still sit­ting in draft. In Oc­to­ber 2025 the drug con­trol­ler un­veiled a draft Drugs, Med­ical Devices and Cos­met­ics Bill, meant to re­tire the 1940 Drugs and Cos­met­ics Act under which devices have long been gov­erned as though they were medi­cines. The head­line change is struc­tural: the bill gives devices their own chapter and their own cat­egory, in­stead of for­cing a scan­ner or a stent through a rule­book writ­ten for mo­lecules.

The re­form lands on a long-run­ning griev­ance. Clin­ical-trial and ap­proval norms built for drugs fit hard­ware and soft­ware badly. Two cau­tions, though. The bill is not yet law; it was pen­cilled in for a par­lia­ment­ary ses­sion and re­mains a draft. And des­pite the new chapter, a genu­inely in­de­pend­ent device reg­u­lator is not con­firmed. Stat­utory power still ap­pears to sit with CDSCO. For now the re­gime is mod­ern­ising in in­tent more than in fact, and the op­er­at­ive rules re­main those of 2017 [In­sert veri­fied en­act­ment status here when the bill passes].

The draft has moved on since this chapter was writ­ten, and so has the op­pos­i­tion to it. The in­stru­ment is now the draft Drugs, Med­ical Devices and Cos­met­ics Bill, 2026. As at 28 Oc­to­ber 2026 el­even in­dustry as­so­ci­ations

con­tin­ued to con­test it, press­ing in­stead for a sep­ar­ate Med­ical Devices Act rather than a device chapter in­side a com­bined stat­ute (Med­ical Buyer, 28 Oc­to­ber 2026). The As­so­ci­ation of In­dian Med­ical Device In­dustry re­it­er­ated at Med­ical Fair India in Septem­ber 2026 that devices war­rant reg­u­lat­ory treat­ment dis­tinct from phar­ma­ceut­ic­als, given the pace of tech­no­lo­gical change.

Sub­or­din­ate rule-mak­ing has not waited for the Bill. In Oc­to­ber 2026 the reg­u­lator is­sued a con­sulta­tion draft on li­cence-ap­plic­a­tion con­tent for do­mestic in-vitro dia­gnostic man­u­fac­tur­ers, im­pos­ing no new ob­lig­a­tions as yet. Along­side it came a pro­posed amend­ment to Rule 30(1) that would per­mit reg­u­lat­ors to order a li­censee to cease man­u­fac­ture or sale of a device and to su­per­vise its de­struc­tion (Med­ical Buyer, 28 Oc­to­ber 2026). En­force­ment powers are there­fore being strengthened under the 2017 rules while the primary le­gis­la­tion re­mains in draft.

The prac­tical po­s­i­tion for a maker is ac­cord­ingly un­changed in sub­stance and less settled in pro­spect. The op­er­at­ive rules re­main those of 2017, as amended, and the reg­u­lator re­mains the Cent­ral Drugs Stand­ard Con­trol Or­gan­isa­tion. The ques­tion of a sep­ar­ate stat­ute and an in­de­pend­ent device reg­u­lator is now a live con­test between the Gov­ern­ment and the in­dustry bod­ies rather than a draft­ing de­tail. Plan­ning should as­sume the present re­gime, with the Bill treated as a risk to timelines rather than a re­lief from them.

MedTechState of Play19 •

The economics of the price cap

No policy shapes the economics of an Indian device more than the price cap, and none divides opinion so sharply.

Noth­ing bends India’s device eco­nom­ics like price con­trol. In 2017 the Na­tional Phar­ma­ceut­ical Pri­cing Au­thor­ity (NPPA) capped coron­ary stents, re­vised every year, with April 2026 ceil­ings of about ₹39,186 for a drug-elut­ing stent and ₹10,762 for a bare-metal one. Knee im­plants were capped too, with that ceil­ing now ex­ten­ded to Novem­ber 2026. The cuts were bru­tal. Pre-cap knee-im­plant mar­gins had run above 300%, and the stent cap more than halved some prices.

What it did to the mar­ket is genu­inely con­tested, and both sides have evid­ence. The de­fin­ing epis­ode came when, after the stent cap, Medtronic and Ab­bott moved to pull their new­est stents from India, cit­ing eco­nom­ics that no longer worked, and the NPPA re­fused to let them leave. In­dustry says the caps scare off fron­tier tech­no­logy and local in­vest­ment; the reg­u­lator says they killed dis­trib­utor mark-ups that did noth­ing for pa­tients. Both are right. The les­son for any maker is plain: in India’s most valu­able cat­egor­ies, the state sets the price, and a cap can ar­rive without warn­ing. Every busi­ness case has to sur­vive one.

Dir­ect ceil­ings are only one of two in­stru­ments, and the second is now the more act­ive. Under the Drugs (Prices Con­trol) Order the Na­tional

In India’s most valuable device categories, the state sets the price. Every business case must survive the cap.

Phar­ma­ceut­ical Pri­cing Au­thor­ity also ap­plies trade-mar­gin ra­tion­al­isa­tion, cap­ping the mar­gin between the price to the dis­trib­utor and the max­imum re­tail price. It has been used on oxi­meters, oxy­gen con­cen­trat­ors, nebulisers and hor­mone-re­leas­ing intra-uter­ine devices, with a fur­ther ex­ten­sion on oxy­gen con­cen­trat­ors no­ti­fied in July 2026. The knee-im­plant ceil­ing stands ex­ten­ded to 15 Novem­ber 2026 (NPPA, 2026).

The Au­thor­ity widened the in­stru­ment's reach in late 2026, al­though not yet to devices. At its 284th meet­ing on 16 Oc­to­ber 2026 it fi­nal­ised a trade-mar­gin cap of 30 per cent of max­imum re­tail price, ex­clud­ing tax and equi­val­ent to a 42.86 per cent mark-up on the price to stock­ist. The cap cov­ers 137 non-sched­uled anti-can­cer drugs, was gaz­etted on 17 Oc­to­ber 2026 and takes ef­fect from 9 Novem­ber 2026. Es­tim­ated an­nual sav­ings are about ₹2,500 crore, with prices fall­ing by up to 70 per cent (Busi­ness Stand­ard, 17 Oc­to­ber 2026). Of­fi­cials are re­por­ted to re­gard ex­ten­sion to devices such as in­tra­ven­ous kits and cath­et­ers as pos­sible.

In­dustry is ar­guing over the basis rather than the prin­ciple. The do­mestic-man­u­fac­turer body has asked for a device frame­work cov­er­ing im­por­ted and do­mestic product alike, with the im­porter treated as the first point of

MedTechState of Play20 •

sale. Its ground is that a 30 per cent cap meas­ured from the dis­trib­utor could still leave im­ports some 43 per cent above do­mestic prices. NITI Aayog and the Au­thor­ity are con­sid­er­ing a device cap in the 30 to 50 per cent band. The Gov­ern­ment stated in a Rajya Sabha reply of 17 March 2026 that no na­tion­wide price cap or single-price frame­work for devices was under con­sid­er­a­tion.

The percentages now in play as trade-margin control moves towards devices
per cent
02040608070Anti-cancer pricefall50Device cap, upper43Imports abovedomestic42.9Mark-up equivalent30Cap on retail price
Source: Business Standard, 17 October 2026

Pub­lic pro­cure­ment com­pounds the dam­age. An in­dustry ana­lysis in 2025 turned up some 1,502 gov­ern­ment tenders worth around ₹63,911 crore that flouted the local-pref­er­ence rules meant to fa­vour In­dian makers, so even where the policy man­dates a home ad­vant­age, the prac­tice often de­faults to im­ports. For a do­mestic man­u­fac­turer the duty struc­ture and the pro­cure­ment gaps weigh as heav­ily as any in­cent­ive; to­gether they de­cide

whether mak­ing in India makes fin­an­cial sense at all. Fix­ing them, cor­rect­ing the in­ver­sion, en­for­cing the pro­cure­ment pref­er­ence, would do more for sub­sti­tu­tion than an­other head­line tar­get. It is the re­form in­dustry asks for most often, and gets least.

The inverted duty, and the own-goal

One line in the tariff schedule undoes more local manufacturing than any subsidy creates.

For all the policy aimed at build­ing a homegrown in­dustry, a single quirk works dir­ectly against it. That quirk is the in­ver­ted duty. A fin­ished med­ical device can often be im­por­ted at zero basic cus­toms duty, while the com­pon­ents needed to build that same device at home at­tract around 7.5%. The res­ult is per­verse. It is fre­quently cheaper to im­port the whole ma­chine than to make it in India, which quietly un­der­cuts the very loc­al­isa­tion the PLI scheme is pay­ing for.

Key takeaways
  • Fin­ished devices im­port at ~0% duty; com­pon­ents at ~7.5%: im­ports beat local pro­duc­tion.
MedTechState of Play21 •
  • ~₹63,911cr of tenders found non-com­pli­ant with local-pref­er­ence rules (2025).
  • Fix­ing duty + pro­cure­ment would do more than an­other tar­get: the re­form in­dustry wants most.

The duty struc­ture is now being reset by trade agree­ment rather than by do­mestic re­form, which cuts against the loc­al­isa­tion case at the mar­gin. The India-United King­dom Com­pre­hens­ive Eco­nomic and Trade Agree­ment entered into force on 15 July 2026. Under it, cus­toms du­ties on se­lec­ted United King­dom-ori­gin devices, ima­ging sys­tems, dia­gnostics and sur­gical in­stru­ments among them, are to be re­duced in tranches from the pre­vail­ing 7.5 to 15 per cent band to­wards ap­prox­im­ately 3 per cent. The gen­er­al­ity of In­dian device ex­ports to the United King­dom se­cures near duty-free ac­cess in re­turn, and a mu­tual-re­cog­ni­tion frame­work eases ac­cess for CDSCO and ICMED-cer­ti­fied product (Med­ical Buyer and Busi­ness Stand­ard, July 2026).

The two in­dustry bod­ies read the same agree­ment in op­pos­ite dir­ec­tions, which is it­self the sec­tor's polit­ics in mini­ature. The mul­tina­tional as­so­ci­ation has char­ac­ter­ised it as a land­mark for the af­ford­ab­il­ity of high-end equip­ment; the do­mestic-man­u­fac­turer as­so­ci­ation con­tin­ues to press for deeper im­port sub­sti­tu­tion and tar­iff pro­tec­tion. Both po­s­i­tions are co­her­ent, and the Gov­ern­ment has so far de­clined to choose, which is the in­con­sist­ency the chapter iden­ti­fies.

A re­form pack­age cov­er­ing pre­cisely these points has been under con­sulta­tion and re­mains un­de­cided. The De­part­ment of Phar­ma­ceut­ic­als

Duty on devices and their components
% basic customs duty
03.87.511.2150Finished device,zero-duty lines3UK-origin devices,post-CETA target7.5Components for localmanufacture15UK-origin devices,upper pre-CETA band
Source: Medical Buyer and Business Standard, 2026

in­vited com­ments on amend­ments to the Global Tender En­quiry ex­emp­tion list, a sched­ule of 354 devices that gov­erns pub­lic-pro­cure­ment ac­cess for im­por­ted equip­ment. The win­dow closed on 15 July 2026, and the re­view re­mained pending at Oc­to­ber 2026. The meas­ures under con­sid­er­a­tion in­clude tar­iff re­view, com­pon­ent in­di­gen­isa­tion, pub­lic-pro­cure­ment in­cent­ives and tax ra­tion­al­isa­tion, with either an ex­ten­sion of the ex­ist­ing in­cent­ive scheme or a ded­ic­ated suc­cessor (India Brief­ing and Med­ical Buyer, 2026).

MedTechState of Play22 •

The part in brief

  1. 01Segment shares are contested: imaging is put near 30 per cent on the older cut, while a reconciled basis makes in-vitro diagnostics largest at 25 to 30 per cent.
  2. 02The export edge is wide rather than deep: consumables are roughly 47 per cent of device exports, and Indian makers now reach some 187 countries.
  3. 03The high-value wall rests on capital and components: an imaging plant needs ₹20 to 100 crore of capital expenditure, and research spending stays below 1 per cent of revenue.
  4. 04Regulation is now a real gate: Class D review takes 120 to 180 days, a clinical investigation costs ₹1 to 5 crore, and over 4,000 manufacturers hold licences.
  5. 05Price and duty decide the economics: the April 2026 drug-eluting stent ceiling is about ₹39,186, while finished imports enter free of duty and components attract 7.5 per cent.
MedTechState of Play23 •
The Mechanics

In India’s most valuable device categories, the state sets the price. Every business case must survive the cap.

03

The Build-Out

The policy, the factories, the firms and the capital trying to close the gap.

The policy push

India’s answer to its import problem is an industrial policy with real money behind it. The question is whether real money is enough.

The gov­ern­ment’s re­sponse is the Na­tional Med­ical Devices Policy, signed off in April 2023. The goal, now fam­ous, is to grow the sec­tor from $11 bil­lion to $50 bil­lion by 2030 and to lift India’s global share from about 1.5% to­ward 10–12% over a quarter-cen­tury. Six pil­lars carry it: single-win­dow reg­u­la­tion, man­u­fac­tur­ing in­fra­struc­ture, R&D, in­vest­ment pro­mo­tion, skilling, and brand-and-ex­port de­vel­op­ment. Un­usu­ally, it is backed by money rather than rhet­oric alone.

The in­stru­ments are real: a ₹3,420 crore pro­duc­tion-linked in­cent­ive scheme, a ₹500 crore pro­gramme to strengthen the in­dustry and its com­pon­ents, a ₹5,000 crore re­search scheme (PRIP). The ar­chi­tec­ture is co­her­ent and the in­tent is ser­i­ous. And yet the head­line tar­get has already been quietly cut, and the deep­est bar­ri­ers, com­pon­ents, R&D, the in­ver­ted duty, are ex­actly the ones a tar­get can­not touch. What the money has ac­tu­ally built is the sub­ject of the next few pages.

The policy also car­ries an im­port tar­get, and it is the least likely of its com­mit­ments to be met. Along­side the mar­ket and global-share ob­ject­ives, the Na­tional Med­ical Devices Policy 2023 seeks to re­duce im­port de­pend­ence

from roughly 70 per cent to­wards 30 per cent and to place India among the world's top five man­u­fac­tur­ing hubs. On the evid­ence of the im­port bill, which rose in FY2025-26 rather than fell, that strand of the policy is mov­ing back­wards.

Central outlays behind the device policy
₹ crore
PRIP research scheme (Oct 20255,000AB PM-JAY senior expansion (Se3,437PLI, medical devices3,420Dedicated MedTech fund (Jan 201,000Strengthening the device indus500Device parks, per park100
Source: Department of Pharmaceuticals and PIB, 2026

The in­stru­ment set has non­ethe­less been ex­ten­ded twice since the policy was signed. A ded­ic­ated med­ical-device in­vest­ment fund of ₹1,000 crore was an­nounced on 28 Janu­ary 2026, the first gov­ern­ment-backed vehicle for the sec­tor alone. It provides equity, quasi-equity and debt in tick­ets of ₹5 to 50 crore to an in­ten­ded forty to sixty com­pan­ies, over­seen by the De­part­ment of Phar­ma­ceut­ic­als and SIDBI, with ap­prox­im­ately ₹500 crore routed through the Re­search, De­vel­op­ment and In­nov­a­tion scheme. The re­search scheme has also begun to dis­burse. In all, 41 pro­jects were

MedTechState of Play24 •

ap­proved under its first call, car­ry­ing ₹1,600 crore of gov­ern­ment as­sist­ance against ₹3,020 crore of ex­pec­ted private in­vest­ment. Nine of them are novel med­ical-device pro­jects and nine­teen are led by star­tups and small en­ter­prises (Med­ical Buyer, 1 Oc­to­ber 2026).

The ar­chi­tec­ture is there­fore sub­stan­tially com­plete, and the open ques­tion has moved from design to up­take. A guid­ing policy, a man­u­fac­tur­ing in­cent­ive, a com­pon­ents-and-cap­ab­il­ity scheme, a parks pro­gramme, a re­search fund, a ded­ic­ated in­vest­ment vehicle, a star­tup sup­port plat­form and a cla­ri­fied reg­u­lat­ory re­gime now exist to­gether. What the money has built, and what it has not, is the sub­ject of the pages that fol­low.

The PLI scheme: what the money built

The production-linked incentive is the policy’s sharpest instrument. Its results are real, and modest against the promise.

The med­ical-device PLI, a ₹3,420 crore pot run­ning to FY27, pay­ing a 5% in­cent­ive on in­cre­mental sales across four seg­ments (can­cer and ra­dio­ther­apy; ima­ging; an­aes­thet­ics and car­dio-res­pir­at­ory; im­plants), is the policy’s most con­crete lever. By late 2025 it had cleared 28 ap­plic­ants, com­mis­sioned 24 green­field pro­jects and put 57 products into pro­duc­tion,

with about ₹157 crore dis­bursed to seven com­pan­ies and cu­mu­lat­ive eli­gible sales of roughly ₹13,625 crore, ₹6,425 crore of it ex­por­ted.

The genu­ine achieve­ment is what now gets built in India that never was be­fore. The list runs to lin­ear ac­cel­er­at­ors, MRI and CT ma­chines, ul­tra­sound and mam­mo­graphy, with C-arms and X-ray sys­tems along­side. This is high-value ima­ging the coun­try once bought whole­sale. Two cau­tions tem­per the win. The eli­gible-sales fig­ure is small against a $16 bil­lion mar­ket, and “made in India” here often means as­sembled from im­por­ted parts, so the value ac­tu­ally loc­al­ised is shal­lower than the out­put sug­gests. The PLI is clos­ing the gap at the mar­gin, in pre­cisely the cat­egor­ies that mat­ter, but at a pace that ex­plains why $50 bil­lion quietly be­came $30 bil­lion.

Quick facts: the PLI scheme
Outlay (FY23–FY27)₹3,420cr
Applicants approved / projects live28 / 24
Products in production57
Cumulative eligible sales~₹13,625cr
Now made locallyCT · MRI · linac

Two fig­ures in the pub­lished re­cord of this scheme were wrong rather than merely out of date, and both should be named be­cause a reader may hold them. Take the first. Cu­mu­lat­ive sales of ₹2,315.44 crore, ex­ports of ₹508.12 crore and im­ports avoided of ₹1,807.32 crore, re­por­ted for

MedTechState of Play25 •

Septem­ber 2025 and widely at­trib­uted to the device scheme, be­long to the bulk-drugs in­cent­ive and are with­drawn. The second is the line "in­vest­ment real­ised ₹33,534 crore against a pro­jec­ted ₹17,275 crore". It be­longs to the Phar­ma­ceut­ic­als in­cent­ive scheme and not to devices, and on that scheme's own basis now stands at ₹46,744 crore as at June 2026 (De­part­ment of Phar­ma­ceut­ic­als, 2026).

Cumulative eligible sales, medical-device PLI
₹ crore
03,7507,50011,25015,00010413.4Mar 202512344.4Sep 202513624.5Dec 2025
Source: Department of Pharmaceuticals, 2026

The device scheme's own dis­burse­ment is more mod­est than the eli­gible-sales fig­ure sug­gests, and be­longs be­side it. Ap­proved pro­jects num­ber 27, car­ry­ing ₹1,153 crore of com­mit­ted in­vest­ment, and ₹266.64 crore had been re­leased as in­cent­ives up to FY2024-25, per the Min­is­ter's Lok Sabha reply of 24 July 2026. Cu­mu­lat­ive eli­gible sales pro­gressed from

₹10,413.40 crore by March 2025 to ₹12,344.37 crore in Septem­ber 2025 and ₹13,624.52 crore by Decem­ber 2025, so the growth is real and the base re­mains small.

The scheme now has an end date, which changes how its res­ults should be judged. The ₹3,420 crore pro­gramme closes in March 2027, and the De­part­ment has said that no fur­ther ap­plic­a­tion rounds are under con­sid­er­a­tion (Med­ical Buyer, 21 Oc­to­ber 2026). Whatever has not been com­mis­sioned by then will not be com­mis­sioned under this in­stru­ment, and the open ques­tion is whether a suc­cessor is cre­ated or the Global Tender En­quiry and duty re­forms carry the bur­den in­stead.

The device parks

Most Indian device makers are too small to build their own labs. The state’s fix, shared parks, also shows how far announcement runs ahead of asphalt.

The policy’s fix is the med­ical device park: shared clusters where com­mon fa­cil­it­ies lower the cost of get­ting star­ted. Roughly three-quar­ters of India’s device makers are small firms that could never af­ford their own test­ing labs, ster­il­isa­tion and ef­flu­ent plants. The scheme sanc­tioned around ₹400 crore, ₹100 crore a park, ori­gin­ally across four states.

MedTechState of Play26 •

The real­ity is a use­ful cor­rect­ive to the press re­leases. The gov­ern­ment now tracks three parks at an ad­vanced stage. They are Greater Noida in Uttar Pra­desh, Uj­jain in Mad­hya Pra­desh and Kan­chipuram in Tamil Nadu, at a total cost of around ₹871 crore. Of that, ₹210 crore has been dis­bursed, with 194 man­u­fac­tur­ers al­lot­ted land across nearly 299 acres and 34 units under con­struc­tion by late 2025. The fourth sanc­tioned park, in Hi­machal Pra­desh, has slipped and ef­fect­ively fallen off the cent­ral count. The parks are real and filling up. The slide from four to three, and the dis­tance between land al­lot­ted and units run­ning, is the whole story in mini­ature, genu­ine, slower than billed, and still early.

Medical device parkStateStatus (late 2025)
Greater NoidaUttar PradeshAdvanced
UjjainMadhya PradeshAdvanced
KanchipuramTamil NaduAdvanced
Himachal PradeshHimachal PradeshDelayed / dropped

The dis­burse­ment re­cord is more pre­cise than the press re­leases and more mod­est than the sanc­tion. Per the Min­is­ter's Lok Sabha reply of 24 July 2026, ₹209.80 crore had been dis­bursed under the Med­ical Device Parks scheme, of which ₹177.98 crore is re­por­ted util­ised. Sep­ar­ately, under the Scheme for Strength­en­ing the Med­ical Device In­dustry, pro­jects of ₹101.50 crore stand ap­proved and ₹88.67 crore has been sanc­tioned

for com­mon fa­cil­it­ies in device clusters. Money com­mit­ted, money re­leased and money spent are three dif­fer­ent fig­ures, and only the last builds any­thing.

Licensed medical-device manufacturing sites by state
licensed sites
Gujarat738Maharashtra721Tamil Nadu346Uttar Pradesh346Haryana302Delhi (NCR)291Karnataka262
Source: CDSCO, 2025

The cent­ral scheme is also not the whole of the park land­scape, and the bench­mark lies out­side it. The Andhra Pra­desh MedTech Zone at Vi­sakhapat­nam, India's first ded­ic­ated med­ical-device zone, oc­cu­pies some 270 acres and re­ceived a sep­ar­ate ₹25 crore com­mon-fa­cil­ity grant. It re­mains the na­tional ref­er­ence for in­teg­rated shared man­u­fac­tur­ing and sci­entific fa­cil­it­ies. State-sponsored ca­pa­city con­tin­ues to be added. The Gu­jarat In­dus­trial De­vel­op­ment Cor­por­a­tion an­nounced on 20 Oc­to­ber 2026 the al­lot­ment of plots at the 336-acre Gu­jarat Med­ical Device Park at

MedTechState of Play27 •

Nagal­par, Ra­jkot, with on­line ap­plic­a­tions open­ing on 26 Oc­to­ber 2026 (Med­ical Buyer, 21 Oc­to­ber 2026).

The parks should there­fore be read as one in­stru­ment among sev­eral in a geo­graphy that is already highly con­cen­trated. Li­censed man­u­fac­tur­ing is weighted heav­ily to­wards the west­ern states, with Gu­jarat and Ma­ha­rashtra alone ac­count­ing for the lar­ger part of na­tional ca­pa­city, against a na­tional total ex­ceed­ing 4,000 sites li­censed since 2021. New parks are chan­ging the mar­gin of that dis­tri­bu­tion rather than its shape.

Money committed, money released and money spent are three different figures, and only the last builds anything.

What makes Poly Med­i­cure a 2026 story rather than a settled one is how it is climb­ing. In 2025 it bought the Dutch firm PendraCare (about ₹189 crore) and Italy’s Cit­ieffe group (about ₹324 crore), pur­chas­ing its way into higher-value car­di­ology and or­tho­paedic-trauma products, and into European mar­kets and know-how. The move is in­struct­ive. Rather than wait years for do­mestic R&D to scale the wall, an In­dian cham­pion is ac­quir­ing the cap­ab­il­ity abroad, a faster, cap­ital-led route that other am­bi­tious makers are likely to copy. At a mar­ket cap­it­al­isa­tion near ₹16,700

crore by mid-2026, Poly Med­i­cure is the tem­plate for what scal­ing looks like.

The exporter: Poly Medicure goes global

India’s clearest device success story never set out to replace an import. It exports, and it is now buying its way upmarket.

If the im­port bill is the prob­lem, Poly Med­i­cure is proof India can build the other half. The lis­ted con­sum­ables maker booked rev­enue of around ₹1,782 crore in FY25, up 21%, and is the coun­try’s largest device ex­porter, ship­ping can­nu­lae, cath­et­ers and in­fu­sion products to more than a hun­dred coun­tries. It is India’s edge made flesh: high-volume, cost-com­pet­it­ive, clin­ic­ally-cred­ible con­sum­ables, scaled on home de­mand and sold to the world.

Key takeaways
  • Poly Med­i­cure: ~₹1,782cr FY25, India’s largest device ex­porter (100+ coun­tries).
  • It is climb­ing the curve by ac­quis­i­tion: PendraCare (NL) and Cit­ieffe (Italy), 2025.
  • The tem­plate: buy the cap­ab­il­ity abroad rather than wait for do­mestic R&D.
MedTechState of Play28 •
Poly Medicure bought European capability for a fraction of its own market value
₹ crore
Market capitalisation16,700FY25 revenue1,782Citieffe, Italy324PendraCare, NL189
Source: company disclosures, 2026

The cat­egory this firm leads is the one in which India's po­s­i­tion is least con­tested, and its struc­ture ex­plains the firm's eco­nom­ics. Con­sum­ables and dis­pos­ables carry low cap­ital in­tens­ity, low im­port de­pend­ence and reg­u­lat­ory classes of B and C rather than D, and scale and cost are the only dur­able moat. The peer group, Hindus­tan Syr­inges, Rom­sons, Ster­imed and Health­ium Medtech, com­petes on the same terms, and Health­ium alone ex­ports across more than 90 coun­tries (re­con­ciled basis and com­pany dis­clos­ures, 2026). It is also the cat­egory with the thin­nest mar­gins.

Ac­quis­i­tion is not the only route up the value curve, and the pub­lic mar­kets have opened as an al­tern­at­ive dur­ing 2026. Mol­bio Dia­gnostics com­pleted a ₹939.70 crore ini­tial pub­lic of­fer­ing in Au­gust 2026, com­pris­ing ₹200 crore of fresh issue and ₹739.70 crore of offer for sale at a band of ₹768 to 807 a share. It was sub­scribed 70.27 times over­all, with the qual­i­fied-in­sti­tu­tional por­tion at 186.39 times, and lis­ted on 17 Au­gust 2026

(BioSpectrum India, Au­gust 2026). Biorad Medisys raised a re­por­ted ₹400 crore pre-list­ing round in July 2026.

Molbio's offering was mostly a sale by existing holders rather than fresh money
₹ crore
02505007501,000939.7Total issue739.7Offer for sale200Fresh issue
Source: BioSpectrum India, August 2026

Read to­gether, the two routes de­scribe how an In­dian device cham­pion now scales. Cap­ab­il­ity at the high-value end is bought abroad, be­cause do­mestic re­search and de­vel­op­ment can­not be grown fast enough to clear the clin­ical and reg­u­lat­ory bar in time. The cap­ital to buy it is raised at home, from pub­lic mar­kets that have be­come re­cept­ive to device and dia­gnostics is­suers. Both halves of that se­quence were un­avail­able a dec­ade ago, and both are more rep­lic­able than a single firm's suc­cess sug­gests.

MedTechState of Play29 •
What makes Poly Medicure a 2026 story rather than a settled one is how it is climbing.

The implant champions: Meril and SMT

Implants are the category India imports most of all. Two homegrown firms are the rare exception that proves it can be done.

If ima­ging is the wall, im­plants are the cit­adel, 88% im­por­ted, the highest-value, highest-trust corner of the mar­ket. Two In­dian firms have breached it. Meril Life Sci­ences, a Gu­jarat maker of car­di­ovas­cu­lar, or­tho­paedic and sur­gical devices, booked around ₹1,730 crore in FY25. It won a land­mark vote of con­fid­ence in July 2025, when the Abu Dhabi In­vest­ment Au­thor­ity paid roughly $200 mil­lion for about 3%, valu­ing the com­pany near $6.6 bil­lion. A PLI-backed plant and plans to mul­tiply rev­enue make it the coun­try’s most cred­ible high-value chal­lenger.

Sahajanand Med­ical Tech­no­lo­gies (SMT), a car­diac-stent and struc­tural-heart spe­cial­ist with rev­enue around ₹1,040 crore, filed for an IPO in July

2025 and won the reg­u­lator’s nod in Novem­ber. That mar­ket debut will test whether in­vestors be­lieve in an In­dian im­plant maker. Between them, Meril and SMT show the cit­adel is not im­preg­nable; In­dian firms can com­pete in stents and struc­tural-heart devices, where de­pend­ence runs deep­est. But the fact that only two names stand out is its own ver­dict on how thin the layer of high-value cham­pi­ons re­mains. The im­plant fron­tier is being con­tested. It is not yet being won.

Implant championFocusFY25 revenue2025 signal
Meril Life SciencesCardiovascular, ortho~₹1,730crADIA ~$200m at ~$6.6bn EV
Sahajanand (SMT)Cardiac stents~₹1,040crIPO approved (Nov)

The cat­egory these two firms con­test is nar­rower than the word im­plant sug­gests, and India's po­s­i­tion within it is un­even. Car­diac and vas­cu­lar devices ac­count for 10 to 12 per cent of the mar­ket, at very high cap­ital in­tens­ity and in reg­u­lat­ory classes C and D, and India is genu­inely com­pet­it­ive in coron­ary stents. Sahajanand Med­ical Tech­no­lo­gies ranks among the world's lar­ger makers there and sells into more than 40 coun­tries, with Translu­mina a third do­mestic name. Rhythm man­age­ment, pace­makers, de­fib­ril­lat­ors and heart valves re­main im­port-led (re­con­ciled basis, 2026).

Meril's sig­ni­fic­ance lies in hav­ing crossed from stents into struc­tural heart, which is where the value and the evid­ence bur­den are greatest. Its Myval tran­scath­eter aor­tic valve is the clearest in­stance of an In­dian firm

MedTechState of Play30 •

com­pet­ing at the fron­tier of the cat­egory rather than at its com­mod­ity end, along­side or­tho­paed­ics, en­dosur­gery and in-vitro dia­gnostics in the same port­fo­lio. Heart valves, stents and dia­lysis products now fea­ture among the out­put of pro­duc­tion-linked in­cent­ive pro­jects (Lok Sabha reply, July 2026).

The cap­ital arith­metic ex­plains why the layer of such firms is thin. An im­plant busi­ness re­quires ₹5 to 50 crore of man­u­fac­tur­ing setup and ₹150 to 400 crore of total cap­ital to reach prof­it­ab­il­ity, over four to seven years. Price ceil­ings are set by the reg­u­lator in ex­actly its richest lines. The sec­tor's new in­sti­tu­tional cap­ital is being raised by people who have made that jour­ney. The ₹1,000 crore ded­ic­ated device fund an­nounced in Janu­ary 2026 is being es­tab­lished as MedArtha Cap­ital by a group led by Ganesh Sabat, formerly chief ex­ec­ut­ive of Sahajanand Med­ical Tech­no­lo­gies.

And it is a pat­tern, not a one-off. Sov­er­eign wealth (ADIA into Meril) and global PE (KKR into Health­ium) now sit along­side do­mestic IPOs (SMT) and over­seas ac­quis­i­tions (Poly Med­i­cure in Europe). The cap­ital ar­riv­ing is pa­tient and in­sti­tu­tional, drawn by the thesis this read keeps re­turn­ing to: a big, struc­tur­ally-grow­ing, under-sup­plied mar­ket with a vast im­port bill to sub­sti­tute. For an in­vestor, Health­ium is the proof the op­por­tun­ity is in­vestable at scale; for the sec­tor, it is the con­sol­id­a­tion that turns dozens of sub-scale makers into a few na­tional cham­pi­ons with the bal­ance sheets to climb.

The consolidation: KKR and Healthium

The surest sign Indian medtech has become an asset class is the calibre of investor now writing the cheques.

In May 2024 the global private-equity firm KKR agreed to buy Bengaluru’s Health­ium Medtech, a maker of sur­gical su­tures, needles and arth­ro­scopy kit, from Apax Part­ners, at an en­ter­prise value of roughly ₹7,000 crore, about $840 mil­lion. The size is not the point. It is one of global private equity’s largest bets on an In­dian device maker, and it marks the mo­ment the sec­tor stopped look­ing like a frag­men­ted cot­tage in­dustry and star­ted look­ing like some­thing in­sti­tu­tions can own.

The terms of the trans­ac­tion mat­ter as much as its size, be­cause they es­tab­lish what the mar­ket will pay. The busi­ness changed hands at roughly twenty times earn­ings be­fore in­terest, tax, de­pre­ci­ation and amort­isa­tion. The buyer pre­vailed over a com­pet­ing con­sor­tium of Man­kind Pharma, ChrysCapital and Novo Hold­ings, which is to say that the price was tested rather than ne­go­ti­ated in isol­a­tion (Bloomberg, Busi­ness Stand­ard and Apax, 2024). The asset had already passed from TPG to Apax in 2018, so the se­quence is a private-equity chain of cus­tody rather than a first in­sti­tu­tional entry.

MedTechState of Play31 •

Be­neath the land­mark deal, the ag­greg­ate flow has moved by an order of mag­nitude. Private-equity and ven­ture in­flows into the In­dian device sec­tor rose from about US$180 mil­lion in 2019 to roughly US$1.25 bil­lion in 2025 (BioSpectrum India and IBEF, 2026). Health­care in­vestors are re­por­ted to be re­dir­ect­ing cap­ital from hos­pital chains to­wards device makers and dia­gnostics busi­nesses, steep hos­pital valu­ations being cited as the prox­im­ate cause (Med­ical Buyer, 2026).

No second trans­ac­tion of com­par­able scale has fol­lowed. In­dian health­care mer­ger and ac­quis­i­tion value in Septem­ber 2026 stood at ₹19 bil­lion. Of that, 88.8 per cent was phar­ma­ceut­ic­als and bi­o­tech­no­logy and about 10 per cent health­care tech­no­logy, with hos­pit­als lead­ing private-equity value and no large device deal re­por­ted (Equirus via Med­ical Buyer, 8 Oc­to­ber 2026). The con­sol­id­a­tion thesis there­fore rests on one con­trol trans­ac­tion, a rising flow of growth cap­ital and a thick­en­ing pub­lic-mar­ket route, rather than on a run of com­par­able deals.

The com­mit­ments are lar­ger and more spe­cific than the chapter's sum­mary con­veys. Medtronic com­mit­ted ap­prox­im­ately ₹3,000 crore in March 2024 to ex­pand its Hy­dera­bad En­gin­eer­ing and In­nov­a­tion Cen­ter, op­er­at­ing since 2011 with more than 1,400 en­gin­eers and its largest re­search site out­side the United States. Siemens Health­in­eers is build­ing an in­teg­rated Bengaluru cam­pus. The cost is €200 mil­lion. It is in­ten­ded to be the firm's largest global site by built-up area, with a fur­ther ₹91.9 crore to loc­al­ise com­puted-tomo­graphy and mag­netic-res­on­ance pro­duc­tion.

Philips has com­mit­ted about €174 mil­lion over six years, in­clud­ing a Pune re­search cam­pus of some 300,000 square feet and around 1,900 staff.

The multinationals in India

The same global giants that fill India’s import bill are quietly starting to build inside the country.

The firms that dom­in­ate India’s im­port bill are no longer just selling into the coun­try. They are put­ting down roots. The pull comes from PLI in­cent­ives, the scale of de­mand, and the cost of In­dian en­gin­eer­ing. Medtronic runs its largest R&D centre out­side the United States in Hy­dera­bad. Wipro GE HealthCare com­mit­ted more than ₹8,000 crore of man­u­fac­tur­ing and R&D over five years in 2024, a PLI-backed fact­ory in­cluded. Siemens Health­in­eers has stood up PLI-backed CT and MRI lines in Bengaluru, where Philips also runs one of its biggest global in­nov­a­tion cam­puses.

The shift is stra­tegic, and double-edged. The mul­tina­tion­als India leans on for im­ports are loc­al­ising pro­duc­tion and re­search, partly to cap­ture in­cent­ives, partly to serve a huge mar­ket cheaply, partly to harden their sup­ply chains. That brings high-value man­u­fac­tur­ing on­shore, which helps the de­fi­cit, but keeps the core tech­no­logy and the deep­est value with the

MedTechState of Play32 •
MultinationalIndia footprint
MedtronicLargest R&D centre outside the US (Hyderabad)
Wipro GE HealthCare>₹8,000cr over 5 yrs; PLI-backed factory
Siemens HealthineersPLI-backed CT & MRI lines, Bengaluru
PhilipsMajor global innovation campus, Bengaluru

global firms, which makes for a shal­lower loc­al­isa­tion than a homegrown in­dustry would de­liver. The mul­tina­tion­als are part of the an­swer to India’s de­pend­ence: on their own terms.

Announced multinational India commitments
₹ crore, as announced
Wipro GE HealthCare, 5 years8,000Medtronic, Hyderabad R&D expan3,000Siemens Healthineers, Bengalur1,910Siemens Healthineers, CT and M91.9
Source: Company announcements via Medical Buyer and Invest India, 2026

Sev­eral oth­ers are build­ing at sim­ilar scale. Stryker opened a 140,000 square foot re­search fa­cil­ity at White­field, Bengaluru in Septem­ber 2025, com­ple­ment­ing a 220,000 square foot Guru­gram cam­pus run­ning since 2006. Bo­ston Sci­entific has a second re­search centre at Pune with 170

en­gin­eers, and Bec­ton Dickin­son has man­u­fac­tured needles and syr­inges at Bawal, Hary­ana since 2011. Zi­m­mer Bio­met stood up a Bengaluru cap­ab­il­ity centre in 2024 and 2025. For­eign dir­ect in­vest­ment of up to 100 per cent is per­mit­ted in device man­u­fac­tur­ing under the auto­matic route, for green­field and brown­field alike.

The scale of the sur­round­ing cap­ab­il­ity base is the part most often missed. India hosts more than 1,800 global de­liv­ery centres em­ploy­ing close to two mil­lion pro­fes­sion­als. Ex­port rev­enue of around US$64.6 bil­lion was gen­er­ated in FY2023-24, with roughly 110 centres added between early 2024 and late 2025 and a tra­ject­ory to­wards 2,100 to 2,400 by 2030 (NASSCOM and in­dustry re­port­ing, 2026). Health­care and med­ical tech­no­logy is among the faster-grow­ing ver­tic­als within it.

The capital and the deals

Capital is pouring in from every direction, sovereign, strategic, public, foreign. The one channel still running dry is venture.

The money has two re­gisters. At the top, big stra­tegic and in­sti­tu­tional cap­ital flows freely. For­eign dir­ect in­vest­ment into the sec­tor hit about $627 mil­lion in FY25, up 30%, on cu­mu­lat­ive FDI of roughly $4.24 bil­lion. Sov­er­eign wealth and global PE have placed land­mark bets (ADIA–Meril,

MedTechState of Play33 •

KKR–Health­ium), and the pub­lic mar­kets are open­ing to device makers (SMT’s ap­proved IPO, Poly Med­i­cure long since lis­ted). For scaled, proven busi­nesses, India’s device sec­tor is now firmly in­vestable.

At the early stage the pic­ture thins and turns cyc­lical. Ven­ture and growth fund­ing into In­dian medtech and healthtech, hard to prise apart from the wider di­gital-health flows, ran around $1 bil­lion in 2025, a reset year after the pan­demic boom. Roughly $310 mil­lion fol­lowed in the first half of 2026. A much-quoted “$9.9 bil­lion” is cu­mu­lat­ive all-time fund­ing, not an­nual, and should not be mis­taken for a flood. The cap­ital mir­rors the mar­ket ex­actly. It is deep and con­fid­ent for the hand­ful of firms that have reached scale, shal­low and choosy for the many that have not. The money goes where the edge is already proven.

Quick facts: the capital
FDI, FY25 (YoY)~$627M (+30%)
Cumulative FDI (to Dec 2025)~$4.24B
KKR–Healthium (2024)~$840M
ADIA into Meril (2025)~$200M
Healthtech VC, 2025 (annual)~$1B

The device-spe­cific fun­nel is the fig­ure to hold, be­cause it is far smal­ler than the health-tech­no­logy totals it is routinely con­fused with. The base stood at ap­prox­im­ately 1,087 device star­tups as at Novem­ber 2025, up

from about 908 a year earlier. Of those, 318 are fun­ded, 48 have reached Series A or bey­ond and 31 Series B or bey­ond, on cu­mu­lat­ive all-time device fund­ing of roughly US$1.23 bil­lion (Tracxn, 2025). Med­ical-device ven­tures ac­count for only some 2 to 3 per cent of In­dian ven­ture activ­ity.

The device funding funnel
companies
Device startups1,087Funded318Series A or beyond48Series B or beyond31
Source: Tracxn, 2025

The an­nual flow is cor­res­pond­ingly small and highly cyc­lical. Device fund­ing ran at about US$132 mil­lion across 36 rounds in 2024 and about US$12.5 mil­lion across 18 rounds in early 2025, a pull­back rather than a trend break. Glob­ally, medtech ven­ture fund­ing of about US$4.1 bil­lion in the second quarter of 2026 sus­tained the firmest pace since 2021, with cap­ital con­cen­trat­ing in fewer and later-stage as­sets. Bengaluru leads on com­pany count at roughly 175 firms, while Mum­bai has be­come the lead­ing hub by value.

Late 2026 shows the same se­lectiv­ity at the level of in­di­vidual rounds. Ul­trahu­man raised US$70 mil­lion on 3 Septem­ber 2026, US$65 mil­lion of

MedTechState of Play34 •

equity and US$5 mil­lion of debt, at a re­por­ted valu­ation of US$365 mil­lion against US$120 mil­lion in 2023 and an an­nual rev­enue run-rate of US$140 mil­lion. Sun­fox Tech­no­lo­gies raised US$7 mil­lion in a Series A on 7 Oc­to­ber 2026, and HRS Nav­ig­a­tion raised about US$5 mil­lion. Bio­scan Re­search raised ap­prox­im­ately US$1 mil­lion in seed on 22 July 2026. Ayati Devices raised ₹15 crore in its first in­sti­tu­tional round. Sev­eral weeks of the period re­cord no veri­fi­able device deal at all.

A much-quoted “$9.9 billion” is cumulative all-time funding, not annual, and should not be mistaken for a flood.

Exports: the edge, sold abroad

Turn the import story over and you get the export story: a precise map of where India already wins.

For all the focus on the im­port bill, India runs a real and grow­ing ex­port busi­ness in ex­actly the cat­egor­ies where its edge is genu­ine. On the gov­ern­ment’s nar­rower trade bas­ket, ex­ports climbed from about ₹18,173 crore in FY19 to ₹31,120 crore in FY25, an 88% jump, around $3.6 bil­lion,

while the broader DGCIS series puts FY25 nearer ₹42,360 crore. The biggest buy­ers are the United States (about 16%), Ger­many, France, China and the Neth­er­lands, and con­sum­ables make up close to half the total.

The ex­port pro­file con­firms the read’s cent­ral split. India sells the world what it makes well, cost-com­pet­it­ive con­sum­ables and dis­pos­ables, with basic dia­gnostics along­side. It buys what it can­not yet make. The firms that an­chor those ex­ports (Poly Med­i­cure fore­most) are the same ones now climb­ing the curve. Ex­ports are not a story apart from sub­sti­tu­tion; they are the re­cord of where sub­sti­tu­tion has already suc­ceeded, and a guide to where it goes next. The prize is to push that ex­port edge up­ward, from dis­pos­ables to­ward devices, even as the im­port bill is at­tacked from below.

The two ex­port series in cir­cu­la­tion move in op­pos­ite dir­ec­tions, so read the bas­ket be­fore the tra­ject­ory. On the dol­lar series, ex­ports rose from about US$1.87 bil­lion in FY2017-18 to about US$2.92 bil­lion in FY2021-22 and about US$3.8 bil­lion in FY2023-24, a com­pound rate of roughly 12 to 14 per cent. They reached about US$4 bil­lion in FY2024-25 (IBEF and India Pharma Out­look, 2026). On the nar­rower trade bas­ket, ex­ports of ₹28,106 crore are re­cor­ded for FY2025-26, which is below the FY2024-25 fig­ure quoted above. The com­par­ison is between bas­kets, not between years. It should not be presen­ted as a de­cline.

The for­ward es­tim­ates di­verge by a factor of two and a half, which is the hon­est state of the evid­ence. The Con­fed­er­a­tion of In­dian In­dustry

MedTechState of Play35 •
Device exports, dollar basis, against the FY2030 industry target
US$ bn
051015201.9FY2017-182.9FY2021-223.8FY2023-244.1FY2024-2520FY2029-30 target
Source: IBEF and CII, 2026

pro­jects ex­ports of up to ₹1,69,000 crore, about US$20 bil­lion, by FY2029-30. That am­bi­tion is car­ried under the in­dustry's '30@2030' fram­ing. It is sup­por­ted by the Ex­port Pro­mo­tion Coun­cil for Med­ical Devices, which con­cluded a memor­andum with the Min­istry of Micro, Small and Me­dium En­ter­prises on 19 July 2026 to strengthen smal­ler man­u­fac­tur­ers' ex­port read­i­ness. Bain & Com­pany, by con­trast, pro­jects growth above 20 per cent com­pound to 2030, which would take ex­ports to nearly US$8 bil­lion.

The one meas­ure on which the sources agree is reach. In­dian device ex­ports now travel to ap­prox­im­ately 187 coun­tries, against some­thing closer to 125 on a nar­rower count, and the in­dustry's own fram­ing has shif­ted from net im­porter to pro­duc­tion and ex­port hub (Med­ical Buyer,

Septem­ber 2026). Reach has widened faster than value, which is con­sist­ent with an ex­port base still weighted to­wards low-unit-cost con­sum­ables.

Clinical AI and software-as-a-medical-device

India may not build the scanner. But it can write the intelligence that reads the scan, and that is the one frontier where it can leap ahead.

The hard­ware wall has a soft­ware door. India’s deep­est ad­vant­age, en­gin­eer­ing and soft­ware tal­ent, maps straight onto the fast­est-grow­ing layer of med­ical tech­no­logy, clin­ical AI and soft­ware-as-a-med­ical-device (SaMD). Firms like Qure.ai (which raised $65 mil­lion), Niramai in breast-can­cer screen­ing and Tricog in car­diac dia­gnostics are build­ing al­gorithms that read scans, triage pa­tients and stretch scarce spe­cial­ist ca­pa­city. That is the exact bot­tle­neck a bed-and-doc­tor-short sys­tem runs into.

The logic is hard to argue with. SaMD draws on the input India has in abund­ance (soft­ware tal­ent) rather than the ones it lacks (pre­ci­sion com­pon­ents, cap­ital-heavy fab­ric­a­tion, dec­ades of hard­ware IP). It scales without factor­ies, and it tackles India’s real clin­ical short­age, not of ma­chines so much as of the ex­pert­ise to use them, which AI mul­ti­plies. The fron­tier has fric­tion. Clin­ical-AI reg­u­la­tion is still matur­ing under CDSCO,

MedTechState of Play36 •

and re­im­burse­ment is un­settled. But of every route up the value curve, soft­ware is the one where India can lead rather than fol­low, build­ing global products from a home base, ex­actly as its IT in­dustry did a gen­er­a­tion ago.

Key takeaways
  • SaMD needs the input India has (soft­ware tal­ent), not the ones it lacks (com­pon­ents, fab IP).
  • Qure.ai, Niramai, Tricog: AI that ex­tends scarce spe­cial­ist ca­pa­city: India’s real bot­tle­neck.
  • The one fron­tier where India can lead, not fol­low: if reg­u­la­tion and re­im­burse­ment keep up.

The flag­ship case is now doc­u­mented well enough to be meas­ured rather than as­ser­ted. Qure.ai, foun­ded in Mum­bai in 2016, has raised ap­prox­im­ately US$123 mil­lion across nine rounds from forty-eight in­vestors. It was val­ued at around ₹2,230 crore in Novem­ber 2024, and re­por­ted rev­enue of ₹190 crore for the year ended 31 March 2025, with de­ploy­ment in more than ninety coun­tries. Its de­fin­ing asset is reg­u­lat­ory rather than tech­nical. There are eight­een United States Food and Drug Ad­min­is­tra­tion clear­ances, with six fur­ther chest-ra­dio­graph in­dic­a­tions cleared in Feb­ru­ary 2026, and a Bill and Melinda Gates Found­a­tion grant in Janu­ary 2026 for point-of-care ul­tra­sound in low- and middle-in­come coun­tries.

The reg­u­lat­ory frame has hardened con­sid­er­ably since this chapter was writ­ten, and it now fa­vours the ser­i­ous entrant. Ar­ti­fi­cial-in­tel­li­gence dia­gnostic soft­ware is a Class C device under the Med­ical Devices Rules 2017. The final Guid­ance Doc­u­ment on Med­ical Device Soft­ware was is­sued in Au­gust 2026, su­per­sed­ing the draft of 21 Oc­to­ber 2025. It provides an Al­gorithm Change Pro­tocol per­mit­ting pre-spe­cified model up­dates without fresh ap­proval. Guid­ance re­por­ted in July 2026 ad­di­tion­ally re­quires dis­clos­ure of train­ing-data com­pos­i­tion and of bias across India-rel­ev­ant sub-pop­u­la­tions (CDSCO, 2026).

The data-pro­tec­tion clock is also now run­ning rather than pending, which is a cor­rec­tion of some con­sequence for any ven­ture whose moat is its data­set. The Di­gital Per­sonal Data Pro­tec­tion Rules were no­ti­fied on 13 Novem­ber 2025 under G.S.R. 846(E) on a phased timetable. Con­sent-man­ager ob­lig­a­tions begin from about Novem­ber 2026. Full com­pli­ance is due by 13 May 2027. Pen­al­ties under the par­ent Act of 2023 reach ₹250 crore per in­stance for ser­i­ous fail­ures. The same pro­pri­et­ary data that con­sti­tutes the product is there­fore also its largest com­pli­ance ex­pos­ure.

The flagship case is now documented well enough to be measured rather than asserted.
MedTechState of Play37 •

The part in brief

  1. 01The policy is funded rather than merely declared: a ₹3,420 crore manufacturing incentive now sits beside a ₹5,000 crore research scheme and a ₹1,000 crore device fund.
  2. 02The incentive's output is real and small: eligible sales reached ₹13,624.52 crore by December 2025, against ₹266.64 crore released as incentives to FY2024-25.
  3. 03The parks are fewer and slower than announced: three remain in the central count at about ₹871 crore, with ₹209.80 crore disbursed and 34 units under construction.
  4. 04Capital has arrived for proven firms: KKR paid about ₹7,000 crore for Healthium, ADIA $200 million for 3 per cent of Meril, and sector inflows hit US$1.25 billion in 2025.
  5. 05Software is the route where India can lead: Qure.ai has raised about US$123 million, holds eighteen United States clearances and deploys in more than ninety countries.
MedTechState of Play38 •
The Build-Out

A much-quoted “$9.9 billion” is cumulative all-time funding, not annual, and should not be mistaken for a flood.

04

The Read

The contrast, the gap, the constraints, and where the market goes.

India versus China

There is one comparison India cannot escape, and it measures both the size of the prize and the difficulty of claiming it.

Every as­sess­ment of In­dian medtech is, un­der­neath, a com­par­ison with China. China set out on the same road two dec­ades earlier and ar­rived where India now wants to be. It built a large do­mestic device in­dustry on sus­tained state sup­port, hard loc­al­isa­tion man­dates, deep com­pon­ent sup­ply chains and heavy R&D. It now ex­ports high-value devices, India in­cluded, where it is poised to be­come a lead­ing source of im­ports. The con­trast stings. India’s device R&D runs below 1% of rev­enue where China’s lead­ers spend many times that.

But the com­par­ison points to India’s own open­ing as much as its lag. India need not re­trace China’s hard­ware-first path. It can lean on dif­fer­ent strengths in­stead, soft­ware and clin­ical AI, frugal in­nov­a­tion for cost-sens­it­ive mar­kets, a vast Eng­lish-speak­ing en­gin­eer­ing base, and a demo­cratic, IP-re­spect­ing set­ting that ap­peals to West­ern part­ners wary of con­cen­trat­ing in China. The “China-plus-one” re­shuffle of med­ical sup­ply chains is a genu­ine tail­wind. India will not out-man­u­fac­ture China this dec­ade. The real ques­tion is whether it can carve out a po­s­i­tion of its own, in soft­ware, in con­sum­ables, in chosen high-value niches, rather than a smal­ler copy of China’s.

The com­par­ison can be set out on six meas­ures, and on each of them the gap is wide rather than mar­ginal. India's do­mestic mar­ket stands at roughly US$15 bil­lion against a Chinese mar­ket well in ex­cess of US$100 bil­lion, the world's second-largest. India is a net im­porter, with ex­ports of about US$4.1 bil­lion in FY2024-25. China is a large net ex­porter. India's im­port de­pend­ence runs 70 to 80 per cent over­all and 80 to 85 per cent at the high end, while China is sub­stan­tially self-re­li­ant across most seg­ments. India holds about 1.6 per cent of the global mar­ket and tar­gets 10 to 12 per cent, while China is among the top two (India Brief­ing, IBEF and In­vest India, 2026).

China's device market dwarfs India's, and India's export base more so again
US$ billion
0255075100100China, market15India, market4.1India, exports
Source: India Briefing, IBEF and Invest India, 2026

The two re­main­ing meas­ures are the ones that gov­ern the pace of catch-up. On com­pon­ent sup­ply, India car­ries a 30 to 40 per cent up­stream

MedTechState of Play39 •

de­pend­ency, much of it on China it­self, against a ver­tic­ally in­teg­rated Chinese com­pon­ent base. On policy vin­tage, India's na­tional policy dates from 2023 and its man­u­fac­tur­ing in­cent­ive from FY2021-22. Chinese loc­al­isa­tion man­dates go back dec­ades. China is also close to 20 per cent of India's own im­port bill, in mon­it­ors, ima­ging com­pon­ents, dis­pos­ables and low-cost dia­gnostics, so de­pend­ence and com­pet­i­tion are the same re­la­tion­ship viewed twice.

The use­ful read­ing is po­s­i­tional rather than com­pet­it­ive. India stands roughly where China stood a dec­ade and more ago: large do­mestic de­mand, rising policy sup­port, and a man­u­fac­tur­ing base climb­ing from as­sembly to­wards com­pon­ents. The gap is widest ex­actly where cap­ital in­tens­ity is highest, in com­pon­ents, ad­vanced ima­ging and high-end im­plants, and nar­row­est in soft­ware, con­sum­ables and dia­gnostics, where India already com­petes.

The 2030 gap

One distance matters more than any other in this story: the gap between what was promised and what is actually happening.

The de­fin­ing ten­sion of In­dian medtech is am­bi­tion against arith­metic. The 2023 tar­get of $50 bil­lion by 2030 needs about 16% growth a year. The mar­ket is doing 5.5 to 8% by in­de­pend­ent counts, which lands it

at $22–27 bil­lion. The gov­ern­ment seems to have ab­sorbed the miss. By March 2026 its min­is­ters were quot­ing $30 bil­lion, roughly halv­ing the goal without ever form­ally drop­ping it. Read plainly, $50 bil­lion was al­ways an as­pir­a­tion dressed as a fore­cast, and the real­istic des­tin­a­tion is the mid-to-high twen­ties of bil­lions.

That re­fram­ing changes how the op­por­tun­ity should be judged. A $26 bil­lion mar­ket in 2030 is still big and still fast-grow­ing, but it is not the trans­form­a­tion the head­line sold, and the im­port bill will likely still be large. Sub­sti­tu­tion is real but gradual, bit­ing where India can com­pete and stalling where it can’t. For an op­er­ator or in­vestor the move is to dis­count the tar­get and trust the trend: build the thesis on real­istic growth and cat­egory-by-cat­egory sub­sti­tu­tion, not on a num­ber the gov­ern­ment no longer quite be­lieves.

The target halved without being abandoned. Discount the ambition; trust the trend, and the trend is still large.

The spread of 2030 es­tim­ates is wider than the chapter's two fig­ures imply, and the spread is it­self the find­ing. Against the policy tar­get of US$50 bil­lion, the Con­fed­er­a­tion of In­dian In­dustry has re­peatedly pro­jec­ted roughly US$44 to 50 bil­lion, while other re­port­ing has car­ried US$41 to 44 bil­lion. Min­is­ters were quot­ing US$30 bil­lion by March 2026. A sep­ar­ate mar­ket es­tim­ate places the sec­tor at US$18.30 bil­lion in 2026 rising to only

MedTechState of Play40 •

US$26.66 bil­lion by 2031, a com­pound rate near 7.82 per cent (Med­ical Buyer and Busi­ness Stand­ard, 2026). Four cred­ible fig­ures for one year, dif­fer­ing by a factor of nearly two, is not a fore­cast.

Competing estimates of the 2030 market
US$ bn
012.52537.55050Policy target (NMDP2023)44CII projection, lowerbound30Ministers' figure,March 202626.7Independent estimate,2031
Source: NMDP 2023, CII and Medical Buyer, 2026

On the or­ganic growth rate, the re­con­ciled basis used in Volge's in­ternal work is 10 to 15 per cent a year. That sits above the 5.5 to 8 per cent mod­elled by some in­de­pend­ent houses and below the near 20 per cent the tar­get re­quires. The arith­metic of the tar­get is there­fore de­mand­ing rather than im­possible. The mar­ket would need to mul­tiply roughly 3.6 times in five years from its FY2024-25 base. The tar­get has never been form­ally with­drawn, which is why the lower of­fi­cial fig­ure and the ori­ginal one con­tinue to cir­cu­late to­gether.

What should be dis­coun­ted is the num­ber, not the dir­ec­tion. A mar­ket in the high twen­ties to mid forties of bil­lions of dol­lars by 2030 is in every ver­sion of the es­tim­ate far lar­ger than today's, and in every ver­sion the im­port bill re­mains sub­stan­tial. The op­er­ator's and the in­vestor's thesis should be built on the growth rate and on cat­egory-by-cat­egory sub­sti­tu­tion, both of which can be ob­served, rather than on a des­tin­a­tion fig­ure that four reput­able sources can­not agree.

The constraints that gate the climb

The demand is certain and the capital is here. What holds India back is a stack of constraints that reinforce one another.

The bar­ri­ers are no mys­tery. They are well doc­u­mented, they feed on each other, and five of them gate the climb:

  • Com­pon­ent de­pend­ence. India im­ports 70–85% of high-value com­pon­ents, so even local as­sembly leaves the deep­est value abroad and ex­poses makers to cur­rency and sup­ply shocks.
  • R&D in­tens­ity. Below 1% of rev­enue against 8–10% in the US and Ger­many; global firms hold roughly 13 times the pat­ents per dol­lar of rev­enue.
MedTechState of Play41 •
  • Qual­ity and reg­u­lat­ory ca­pa­city. Only a hand­ful of cent­ral test­ing labor­at­or­ies, a CDSCO in­spector short­age, and an in­dustry that is 70–75% small en­ter­prises for whom cer­ti­fic­a­tion is a fin­an­cial bar­rier.
  • Price con­trols. Hard caps in the highest-value cat­egor­ies com­press the mar­gins that would fund R&D and scale.
  • Tal­ent. Bio­med­ical-en­gin­eer­ing ca­pa­city is thin and, by some meas­ures, fall­ing, with the coun­try short of tens of thou­sands of qual­i­fied tech­ni­cians and en­gin­eers.

None of this is in­tract­able, but none of it is quick. Each de­mands sus­tained, un­glam­or­ous re­form rather than one de­cis­ive stroke. The work is fix­ing the duty in­ver­sion and build­ing test­ing ca­pa­city, fund­ing com­pon­ent man­u­fac­tur­ing and grow­ing the tal­ent base. How fast those hap­pen sets the pace of sub­sti­tu­tion, which is why the real­istic path runs below the tar­get.

Two of these con­straints can be quan­ti­fied more closely, and the quan­ti­fic­a­tion is un­flat­ter­ing. On qual­ity and reg­u­lat­ory ca­pa­city, the sanc­tion of 1,500 ad­di­tional posts within the reg­u­lator was con­firmed in 2026. That is an ad­mis­sion of the scale of the ex­ist­ing short­fall rather than a solu­tion to it. Con­form­ity to the Bur­eau of In­dian Stand­ards Scheme X be­came a con­di­tion of law­ful man­u­fac­ture and im­port for no­ti­fied devices from 1 Septem­ber 2026. ISO 13485 qual­i­fic­a­tion takes six to twelve months and costs ₹10 to 30 lakh, a real bar­rier for an in­dustry that is 70 to 75 per cent small en­ter­prises.

On re­search, the bind­ing con­straint is trans­la­tion rather than in­ven­tion. Med­ical tech­no­logy and bi­o­tech­no­logy to­gether ac­count for roughly 10 per cent of pat­ents filed in India, com­par­able to com­puter tech­no­logy, yet most pub­lished re­search does not reach a mar­ket. The clearest evid­ence is the out­put of the strongest trans­la­tional centres. The Health­care Tech­no­logy In­nov­a­tion Centre at IIT Madras has car­ried six products to mar­ket. The Bio­med­ical En­gin­eer­ing and Tech­no­logy In­nov­a­tion Centre at IIT Bom­bay re­ports 450 doc­u­mented unmet needs, 55 pat­ents filed, 25 devices, 16 star­tups in­cub­ated and 14 products li­censed to in­dustry. Those are com­mend­able num­bers for a centre and small ones for a coun­try.

The translation funnel at one leading centre narrows sharply at every step
count
Unmet needs logged450Patents filed55Devices developed25Startups incubated16Products licensed14
Source: IIT Bombay

The at­tri­tion this im­plies is steep. Between 30 and 40 per cent of fun­ded In­dian medtech star­tups are ex­pec­ted to fail or be ac­quired within a two-year ho­ri­zon, and only 48 of 318 fun­ded device com­pan­ies have reached Series A or bey­ond. None of the five con­straints is in­tract­able; each

MedTechState of Play42 •

re­quires sus­tained and un­glam­or­ous re­form; and the pace of that re­form, not the am­bi­tion above it, sets the pace of sub­sti­tu­tion.

Market access, and what could go wrong

The way into Indian medtech is navigable. The hazards along it are specific, and worth naming.

For a maker or in­vestor, mar­ket ac­cess now runs through a defined gate. That gate is CDSCO li­cens­ing by risk class, the price caps in reg­u­lated cat­egor­ies, pub­lic-pro­cure­ment pref­er­ence rules, and, for any­one build­ing loc­ally, the PLI in­cent­ives and the device parks. The work­able strategies cluster into three: loc­al­ise to cap­ture PLI and pro­cure­ment pref­er­ence; part­ner a do­mestic cham­pion for dis­tri­bu­tion and reg­u­lat­ory nav­ig­a­tion; or com­pete in soft­ware and con­sum­ables, where the bar­ri­ers are low­est and India’s edge is real.

Three risks could bend the path. The first is policy in­con­sist­ency, the gap between the duty sched­ule and the loc­al­isa­tion goal, or a price cap land­ing without warn­ing, can void a busi­ness case overnight; the Medtronic-and-Ab­bott stent af­fair is the warn­ing. The second is that sub­sti­tu­tion simply stalls, leav­ing the im­port bill stub­bornly high and the tar­get out of

reach. The third is that “China-plus-one” dis­ap­points: the sup­ply-chain re­shuffle India is count­ing on may fa­vour other low-cost makers, or China may tighten its grip on the In­dian im­port mar­ket in­stead. None of these re­verses a struc­tur­ally grow­ing mar­ket. Each de­cides who cap­tures it, and how fast.

Key takeaways: access
  • Three vi­able plays: loc­al­ise (PLI), part­ner a cham­pion, or com­pete in soft­ware/con­sum­ables.
  • The sharpest risk is policy in­con­sist­ency: a cap or duty quirk can void a busi­ness case.
  • Watch China-plus-one: a hoped-for tail­wind that is not guar­an­teed to fa­vour India.

The gate has be­come more spe­cific since this chapter was writ­ten. The dates are now the op­er­at­ive de­tail. Con­form­ity to Bur­eau of In­dian Stand­ards Scheme X has been re­quired for no­ti­fied devices since 1 Septem­ber 2026. The 354-device Global Tender En­quiry ex­emp­tion list, which gov­erns pub­lic-pro­cure­ment ac­cess for im­por­ted equip­ment, closed for con­sulta­tion on 15 July 2026 and re­mained un­de­cided at Oc­to­ber 2026. The India-United King­dom trade agree­ment entered into force on 15 July 2026, car­ry­ing a mu­tual-re­cog­ni­tion frame­work that eases United King­dom ac­cess for CDSCO and ICMED-cer­ti­fied product. Full com­pli­ance with the data-pro­tec­tion rules falls due on 13 May 2027.

MedTechState of Play43 •

The sup­port in­stru­ments are equally spe­cific and are open rather than an­nounced. Under the Scheme for Strength­en­ing the Med­ical Device In­dustry, as­sist­ance of up to ₹5 crore per ap­plic­ant is avail­able for clin­ical in­vest­ig­a­tion and post-mar­ket fol­low-up stud­ies. A one-time re­im­burse­ment cap­ital sub­sidy of up to ₹10 crore is also on offer, for do­mestic pro­duc­tion of com­pon­ents, raw ma­ter­i­als and fin­ished devices presently im­por­ted in quant­ity. The Star­tup India Fund of Funds 2.0, a ₹10,000 crore scheme no­ti­fied in 2026, widens the run­way for device, dia­gnostics and soft­ware ven­tures.

One risk, in its 2026 form, now sits closer than this chapter al­lows. The trade-mar­gin in­stru­ment, ap­plied to 137 anti-can­cer drugs with ef­fect from 9 Novem­ber 2026, is re­por­ted to be under con­sid­er­a­tion for devices such as in­tra­ven­ous kits and cath­et­ers. A pro­posed amend­ment to Rule 30(1) would per­mit reg­u­lat­ors to order a li­censee to cease man­u­fac­ture or sale and to su­per­vise de­struc­tion of a device. Policy in­con­sist­ency re­mains the sharpest haz­ard, and it is now a ques­tion of which in­stru­ment ar­rives first rather than whether one does.

The support instruments are equally specific and are open rather than announced.

The bind­ing ques­tion is whether the struc­tural re­forms move fast enough to push sub­sti­tu­tion past mere as­sembly. Those re­forms are the duty

in­ver­sion and com­pon­ent man­u­fac­tur­ing, with test­ing ca­pa­city and tal­ent along­side. The mar­ket reaches the mid-to-high twen­ties of bil­lions by 2030 either way. Whether India cap­tures a grow­ing share of it, or stays a great buyer, comes down to those un­glam­or­ous fixes.

The next two to three years

What Indian medtech should look like by 2028, if the next three years run true to form.

Over the next two to three years, the device mar­ket will keep grow­ing hard and sub­sti­tut­ing se­lect­ively, its centre of grav­ity shift­ing in ways you can already see. Four de­vel­op­ments look most likely:

  • Con­sol­id­a­tion ac­cel­er­ates. Fol­low­ing KKR–Health­ium and ADIA–Meril, ex­pect more PE and sov­er­eign cap­ital to roll up sub-scale makers into na­tional cham­pi­ons, and more In­dian firms to buy cap­ab­il­ity abroad, as Poly Med­i­cure has.
  • The high-value cat­egor­ies loc­al­ise, shal­lowly. PLI-backed ima­ging and se­lect­ive im­plants will be in­creas­ingly “made in India,” but com­pon­ent de­pend­ence keeps the loc­al­isa­tion thin and the deep­est value abroad.
  • Soft­ware leads. Clin­ical AI and SaMD will be the fast­est-grow­ing and most glob­ally-com­pet­it­ive layer: the area where In­dian firms build genu­ine in­ter­na­tional products.
MedTechState of Play44 •
  • The reg­u­lat­ory re­gime mod­ern­ises. The new devices bill, if en­acted, fi­nally sep­ar­ates devices from drugs, and CDSCO ca­pa­city slowly catches up with its ex­pan­ded remit.

Sev­eral of these de­vel­op­ments now carry dates. The next three years are un­usu­ally legible. The med­ical-device pro­duc­tion-linked in­cent­ive closes in March 2027, and the De­part­ment has said that no fur­ther ap­plic­a­tion rounds are under con­sid­er­a­tion. A suc­cessor in­stru­ment or a duty-and-pro­cure­ment re­form must there­fore carry the sub­sti­tu­tion agenda from that point. Full com­pli­ance with the data-pro­tec­tion rules falls due on 13 May 2027. The draft Drugs, Med­ical Devices and Cos­met­ics Bill, 2026 re­mains con­tested by el­even in­dustry as­so­ci­ations seek­ing a sep­ar­ate Med­ical Devices Act, so the reg­u­lat­ory mod­ern­isa­tion lis­ted above should be read as prob­able rather than sched­uled.

The re­search and cap­ital in­stru­ments, by con­trast, are already dis­burs­ing. The re­search and in­nov­a­tion scheme ap­proved 41 pro­jects under its first call, with ₹1,600 crore of gov­ern­ment as­sist­ance against ₹3,020 crore of ex­pec­ted private in­vest­ment. Nine of them are novel device pro­jects and nine­teen are led by star­tups and small en­ter­prises. A ded­ic­ated ₹1,000 crore device fund is being stood up to de­ploy equity, quasi-equity and debt in tick­ets of ₹5 to 50 crore. Both are in­stru­ments of the com­pon­ent-and-cap­ab­il­ity prob­lem rather than of final as­sembly, which is the right tar­get.

The research scheme's first call leans more on private money than on public
₹ crore
01,0002,0003,0004,0003,020Private, expected1,600Government assistance1,000Device fund
Source: Medical Buyer, 2026

The like­li­est shape of the period is ac­cord­ingly ex­port-led rather than sub­sti­tu­tion-led. Bain & Com­pany pro­jects device ex­ports grow­ing above 20 per cent com­pound to 2030, po­ten­tially reach­ing nearly US$8 bil­lion. India is es­tim­ated to be cap­able of emer­ging as a US$7 bil­lion con­tract-man­u­fac­tur­ing hub by 2035 (Med­ical Buyer, 2026). Both of those routes build cap­ab­il­ity for other people's products. That cap­ab­il­ity comes first. Whether it con­verts into In­dian-owned high-value devices is the ques­tion the dec­ade after this one will an­swer.

So the op­por­tun­ity is real but un­even, taken cat­egory by cat­egory. India already wins the low-value end and ex­ports it. It still im­ports the high-value end and struggles to build it. Its clearest path to lead rather than fol­low runs through soft­ware, clin­ical AI and SaMD, where it can draw on the

MedTechState of Play45 •

tal­ent it has in­stead of the com­pon­ents it lacks. The cap­ital has worked this out. It pools where the edge is proven.

The read, on a page

The whole argument, in one place, with the evidence behind it.

India’s medtech mar­ket is big, struc­tur­ally grow­ing, and defined by one asym­metry. It buys far more than it makes. The roughly $8 bil­lion im­port bill, widen­ing, not clos­ing, is the exact meas­ure of the op­por­tun­ity. The policy ma­chinery be­hind clos­ing it is real: a na­tional policy, a ₹3,420 crore PLI scheme, device parks, a mod­ern­ising reg­u­lator. But am­bi­tion keeps out­run­ning arith­metic. The $50 bil­lion-by-2030 tar­get has quietly be­come $30 bil­lion against an ana­lyst trend of $22–27 bil­lion. The deep­est bar­ri­ers, com­pon­ent de­pend­ence, thin R&D, price con­trols, the in­ver­ted duty, are the ones no tar­get can fix.

India will reach the mid-twenties of billions by 2030. Whether it makes that market, or merely buys it, is the open question.

For the op­er­ator and the in­vestor, the read is to dis­count the head­line and trust the struc­ture. The struc­ture is a vast, under-sup­plied, grow­ing

mar­ket, sub­sti­tut­ing se­lect­ively, won by who­ever solves the com­pon­ent-and-cap­ab­il­ity prob­lem one cat­egory at a time.

Three cor­rec­tions should be car­ried for­ward with this read, be­cause a reader may hold the su­per­seded fig­ures. Take the first. The pro­duc­tion-linked in­cent­ive num­bers most often quoted for devices, cu­mu­lat­ive sales of ₹2,315.44 crore, ex­ports of ₹508.12 crore and im­ports avoided of ₹1,807.32 crore, be­long to the bulk-drugs scheme and are with­drawn. The device scheme's own cu­mu­lat­ive eli­gible sales stood at ₹13,624.52 crore to Decem­ber 2025, of which ₹6,425.48 crore was ex­por­ted, with 24 green­field pro­jects com­mis­sioned and 57 products in pro­duc­tion. Second, the line "in­vest­ment real­ised ₹33,534 crore against ₹17,275 crore" be­longs to the Phar­ma­ceut­ic­als scheme and now reads ₹46,744 crore as at June 2026. Third, the device scheme closes in March 2027 with no fur­ther ap­plic­a­tion rounds.

Two meas­ure­ment bases have also moved, and both should be stated as ranges. Device im­ports are now car­ried at ₹89,000 to 94,700 crore for FY2025-26 de­pend­ing on the trade bas­ket ap­plied, against ex­ports of ₹28,106 crore. The Gov­ern­ment's own state­ment is that im­ports meet about 60 per cent of do­mestic con­sump­tion. The mar­ket is re-based to a FY2025-26 row of about US$15 to 16 bil­lion, with the band of US$12 to 18 bil­lion held and the com­pet­ing es­tim­ates named rather than av­er­aged. EY and CII put FY2025-26 at US$12 to 15 bil­lion, in­dustry re­port­ing at US$15 to 16 bil­lion, and one house at US$18.3 bil­lion.

MedTechState of Play46 •
Three readings of the same year's market, taken at the top of each range
US$ billion, upper end of range
0510152018.3Research house16Industry reporting15EY and CII
Source: EY and CII

None of this changes the ar­gu­ment, and all of it changes its pre­ci­sion. The im­port bill re­mains the meas­ure of the prize, and the prize re­mains un­even across the eight cat­egor­ies. The com­pon­ent layer and the re­search in­tens­ity be­neath the fin­ished device re­main the bind­ing con­straints. The data-pro­tec­tion rules no­ti­fied on 13 Novem­ber 2025, phas­ing to full com­pli­ance on 13 May 2027, are now a live ob­lig­a­tion for every con­nec­ted and soft­ware-led device rather than a pro­spect­ive one.

Key takeaways

Nine conclusions for the people who must act on this market.

  1. The im­port bill is the prize. ~70% im­por­ted (85% of high-value) against a ~$16B mar­ket: the de­fi­cit is the size of the loc­al­isa­tion op­por­tun­ity.
  2. Sub­sti­tu­tion is eight mar­kets, not one. India wins the low-value end and im­ports the high: the cat­egor­ies move at dif­fer­ent speeds.
  3. The tar­get out­ran the arith­metic. $50B be­came $30B against a $22–27B trend; dis­count the am­bi­tion, trust the trend.
  4. The edge is real but bounded. Con­sum­ables, basic IVD and oph­thal­mo­logy are won; the high-value wall res­ists.
  5. The con­straint is the com­pon­ent. 70–85% of high-value com­pon­ents im­por­ted: local as­sembly leaves the deep­est value abroad.
  6. The state sets the price. NPPA caps in the highest-value cat­egor­ies com­press the mar­gins that fund R&D.
  7. Fix the duty, not the tar­get. The in­ver­ted duty makes im­ports cheaper than local pro­duc­tion: the re­form that mat­ters most.
  8. Soft­ware is where India can lead. Clin­ical AI and SaMD need the tal­ent India has, not the com­pon­ents it lacks.
  9. The cap­ital has ar­rived. KKR, ADIA and the pub­lic mar­kets prove the sec­tor is in­vestable at scale: for proven firms.
MedTechState of Play47 •

Volge's expertise in MedTech

The engineering work the sector asks for, and the form it takes on an engagement.

Med­ical devices are now net­worked products under reg­u­lat­ory su­per­vi­sion, so the en­gin­eer­ing they need sits across se­cur­ity, data and com­pli­ance at once. The work below is what device makers, hos­pital groups and in­vestors in this mar­ket com­mis­sion. Each is de­livered by senior en­gin­eers work­ing in­side the cli­ent's own team, with the Global De­liv­ery Centres run­ning what has been built once it is in pro­duc­tion.

A man­u­fac­turer in India should settle its reg­u­lat­ory clas­si­fic­a­tion and its qual­ity sys­tem be­fore it designs for scale. The li­cens­ing re­gime sorts devices by risk class, and the evid­ence re­quired dif­fers sharply between those classes (Cent­ral Drugs Stand­ard Con­trol Or­gan­isa­tion, 2017). Class de­cides the evid­ence, and the evid­ence de­cides the timetable. Get­ting that wrong late is ex­pens­ive. Volge's first pass is usu­ally a gap re­view against the ap­plic­able class rather than against a gen­eral stand­ard, be­cause a gen­eral stand­ard flat­ters al­most every­body who reads it.

Qual­ity man­age­ment is an op­er­at­ing dis­cip­line, not a cer­ti­fic­ate on a wall. The in­ter­na­tional stand­ard for med­ical device qual­ity sys­tems re­quires design his­tory and change con­trol that are cur­rent at any mo­ment, not at audit time (In­ter­na­tional Or­gan­isa­tion for Stand­ard­isa­tion, 2016). Di­git­ising

that re­cord is or­din­ary en­gin­eer­ing and it is rarely done well. Sub­mis­sions then draw on it dir­ectly. A man­u­fac­turer whose design his­tory lives in spread­sheets pays for it twice, once at li­cens­ing and again at the first field com­plaint.

An en­gage­ment of this kind runs in se­quence, be­cause the arte­facts de­pend on one an­other. Product and asset data have to exist be­fore qual­ity di­git­isa­tion can be scoped, and the qual­ity re­cord has to exist be­fore a sub­mis­sion pack­age is cred­ible. The open­ing quarter is there­fore nar­row. It cov­ers one product fam­ily, with a di­git­ised design his­tory and a sur­veil­lance pipeline be­hind it. Volge em­beds en­gin­eers in­side the cli­ent's own qual­ity and reg­u­lat­ory func­tions, under an ar­chi­tect who stays through the first sub­mis­sion.

Meas­ure­ment should track the re­cord, not the pro­ject. Time from design change to ap­proved doc­u­ment­a­tion, and time from field com­plaint to closed in­vest­ig­a­tion, are the two num­bers that pre­dict whether a li­cence sur­vives in­spec­tion. Neither is ex­pens­ive to meas­ure. The com­mon fail­ures are fa­mil­iar enough, in that firms di­git­ise the qual­ity sys­tem without chan­ging who owns it, and scope cy­ber­se­cur­ity for the device alone when the reg­u­lator is now ask­ing about its gate­way and its cloud ser­vice too.

Device security and resilience
  • Med­ical device se­cur­ity re­view, against IEC 62443 and the pre­market cy­ber­se­cur­ity ex­pect­a­tions of the CDSCO and the FDA.
MedTechState of Play48 •
  • Clin­ical net­work seg­ment­a­tion, sep­ar­at­ing dia­gnostic and thera­peutic devices from the hos­pital cor­por­ate net­work.
  • Device threat mod­el­ling and pen­et­ra­tion test­ing, on the device, its gate­way and its cloud ser­vice.
  • Co­ordin­ated vul­ner­ab­il­ity dis­clos­ure and patch pro­grammes for a fielded device pop­u­la­tion.
Device data and operations
  • Med­ical device in­vent­ory man­age­ment, build­ing and main­tain­ing a single asset re­gister across sites.
  • Device util­isa­tion and ser­vice ana­lyt­ics, link­ing up­time and main­ten­ance to clin­ical through­put.
  • In­ter­op­er­ab­il­ity en­gin­eer­ing, bring­ing device out­put into the re­cord through HL7 FHIR and na­tional ex­changes.
  • Unique device iden­ti­fic­a­tion and seri­al­isa­tion across man­u­fac­tur­ing and dis­tri­bu­tion.
Regulatory and quality engineering
  • Sub­mis­sion data pack­ages for CDSCO li­cens­ing and Bur­eau of In­dian Stand­ards Scheme X con­form­ity.
  • Qual­ity man­age­ment sys­tem di­git­isa­tion to ISO 13485, in­clud­ing design his­tory and change con­trol.
  • Post-mar­ket sur­veil­lance and vi­gil­ance re­port­ing, with the data pipeline that feeds it.
  • Val­id­a­tion and model gov­ernance for soft­ware as a med­ical device, in­clud­ing dia­gnostic ar­ti­fi­cial in­tel­li­gence.
How an engagement runs
  • A dia­gnosis of two to eight weeks, led on site by senior ar­chi­tects, es­tab­lish­ing the device pop­u­la­tion and its ex­pos­ure.
  • A se­quenced pro­gramme, be­cause an asset re­gister has to exist be­fore seg­ment­a­tion or vul­ner­ab­il­ity work can be scoped.
  • Build teams em­bed­ded along­side the cli­ent's own en­gin­eers rather than work­ing to a spe­cific­a­tion at arm's length.
  • Run and op­er­ate from the Global De­liv­ery Centres, with the design his­tory and sur­veil­lance re­cord kept cur­rent.
MedTechState of Play49 •
The Read

India will reach the mid-twenties of billions by 2030. Whether it makes that market, or merely buys it, is the open question.

Sources

The bodies cited in this read for market size, trade, policy and funding figures, with the year the text attributes to each.

MedTechState of Play50 •
Version · VSP-IMT-001 · 2026
volgeEnable Powerful
Transformations
About Volge

Volge is an engineering firm providing enterprise technology transformation services to clients across the Middle East, India, APAC, Europe, and North America.

Delivery stands on two pillars: Forward Deployed Engineering, with senior specialists embedded in the client’s own team, and Intelligent Command Centre Operations, run from our Global Delivery Centres, which keeps what they build running. Senior engineers stay with an engagement from the first diagnosis through to production.

Our services span Strategy, Data, Platforms, AI and Automation, Cyber Trust, Technology Operations, and Applied Functional Engineering. Engagements begin with a diagnosis. The firm is built on working autonomy: engineers decide, innovate, co-create, and own their work. Motivated engineers build the systems that sustain our clients’ growth.

Terms of use

This edition may be shared with organisations evaluating a Volge engagement. It may not be altered or republished without Volge’s permission, and figures carry their stated basis and date. Volge, Intelligent Command Centre, and Intelligent Command Centre Operations are marks of Volge; other names are the trademarks of their respective owners.